Document:

EX-10.1

 Exhibit 10.1 

Targa Resources Partners LP 

and 
 Targa Resources
Partners Finance Corporation 
 $1,000,000,000 4.875% Senior Notes Due 2031 

PURCHASE AGREEMENT 

August 11, 2020 
 Wells Fargo Securities, LLC

 As representative of the 
 several Initial Purchasers listed

 in Schedule 1 hereto 
 Wells Fargo Securities, LLC 

550 South Tryon Street, 5th Floor 

Charlotte, NC 28202 
 Ladies and Gentlemen: 

Targa Resources Partners LP, a limited partnership organized under the laws of Delaware (the “Partnership”), along with Targa
Resources Partners Finance Corporation, a Delaware corporation (“Finance Co” and, together with the Partnership, the “Issuers”), hereby confirm their agreement with the several Initial Purchasers listed in
Schedule 1 hereto (the “Initial Purchasers”) for whom Wells Fargo Securities, LLC is acting as representative (the “Representative”) as set forth below. 

Targa Resources GP LLC, a Delaware limited liability company (the “General Partner”), owns a 2% general partnership interest
in the Partnership. The Partnership’s direct or indirect majority-owned subsidiaries are listed in Schedule 2 hereto and are referred to herein as the “Subsidiaries”; and the Subsidiaries listed in Schedule 3
hereto are referred to herein as the “Non-Guarantor Subsidiaries.” 

Section 1. The Securities. Subject to the terms and conditions herein contained, the Issuers propose to issue and sell to the
Initial Purchasers $1,000,000,000 aggregate principal amount of their 4.875% Senior Notes due 2031 (the “Notes”), which will be unconditionally guaranteed on a senior basis as to principal, premium, if any, and interest (the
“Guarantees”) by the Subsidiaries of the Partnership named in Schedule 4 hereto (each individually, a “Guarantor” and collectively, the “Guarantors” and, together with the entities named in
Schedule 5 hereto, the “Material Subsidiaries”). The Guarantors, other than Targa SouthOk NGL Pipeline LLC, an Oklahoma limited liability company (“SouthOk”), are referred

 
to herein as the “Covered Guarantors,” and the Guarantors, other than the entities named on Schedule 6 hereto, are referred to herein as the “Non-Excluded Guarantors.” The Notes are to be issued under an indenture (the “Indenture”) to be dated as of August 18, 2020, by and among the Issuers, the Guarantors and U.S. Bank
National Association, as Trustee (the “Trustee”). 
 The Notes will be offered and sold to the Initial Purchasers without
being registered under the Securities Act of 1933, as amended (the “Act”), in reliance on exemptions therefrom. 
 In
connection with the sale of the Notes, the Issuers have prepared a preliminary offering memorandum dated August 11, 2020 (including any documents incorporated therein by reference, the “Preliminary Memorandum”) setting forth or
including a description of the terms of the Notes, the terms of the offering of the Notes, a description of the Partnership and any material developments relating to the Partnership after the date of the most recent historical financial statements
included therein. As used herein, “Pricing Disclosure Package” shall mean the Preliminary Memorandum, as supplemented or amended by the written communications listed on Annex A hereto, in the most recent form that has been
prepared and delivered by the Issuers to the Initial Purchasers in connection with their solicitation of offers to purchase Notes prior to the time when sales of the Notes were first made (the “Time of Execution”). Promptly after
the Time of Execution and in any event no later than the second Business Day following the Time of Execution, the Issuers will prepare and deliver to each Initial Purchaser a final offering memorandum (including any documents incorporated therein by
reference, the “Final Memorandum”), which will consist of the Preliminary Memorandum with such changes therein as are required to reflect the information contained in the amendments or supplements listed on Annex A hereto.
The Issuers hereby confirm that each of the Issuers has authorized the use of the Pricing Disclosure Package, the Final Memorandum and the Recorded Road Show (defined below) in connection with the offer and sale of the Notes by the Initial
Purchasers. 
 All references in this Agreement to financial statements and schedules and other information which are “contained,”
“included” or “stated” in the Offering Memorandum (as defined below) (or other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which are
incorporated by reference in the Offering Memorandum; and all references in this Agreement to amendments or supplements to the Offering Memorandum shall be deemed to mean and include the filing of any document under the Securities Exchange Act of
1934, as amended (the “Exchange Act”) which is incorporated by reference in the Offering Memorandum. 
 The Initial
Purchasers and their direct and indirect transferees of the Notes will be entitled to the benefits of a Registration Rights Agreement (the “Registration Rights Agreement”), pursuant to which the Issuers and the Guarantors will
agree, among other things, to file a registration statement with the Securities and Exchange Commission (the “Commission”) registering the Notes or the Exchange Notes (as defined in the Registration Rights Agreement) under the Act,
unless (i) the Notes are freely transferable without volume restrictions by holders that are not affiliates of the Issuers in accordance with Rule 144 (or any similar provision then in effect), (ii) the Notes do not bear a restrictive legend
and (iii) the Notes do not bear a restricted CUSIP number as of the 370th day after the Closing Date. 

  
 2 

 Section 2. Representations and Warranties. As of the Time of Execution and at
the Closing Date, the Issuers and the Guarantors jointly and severally represent and warrant to and agree with each of the Initial Purchasers as follows (references in this Section 2 to the “Offering Memorandum” are to
(i) the Pricing Disclosure Package in the case of representations and warranties made as of the Time of Execution and (ii) both the Pricing Disclosure Package and the Final Memorandum in the case of representations and warranties made at
the Closing Date): 
 (a) The Preliminary Memorandum, on the date thereof, did not contain any untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. At the Time of Execution, the Pricing Disclosure Package did not, and on the Closing
Date, will not, and the Final Memorandum as of its date and on the Closing Date will not contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; provided, however, that the Issuers and the Guarantors make no representation or warranty as to the information contained in or omitted from the Pricing Disclosure Package and Final
Memorandum, in reliance upon and in conformity with information furnished in writing to the Partnership by or on behalf of the Initial Purchasers through the Representative specifically for inclusion therein. The Issuers and the Guarantors have not
distributed or referred to and will not distribute or refer to any written communications (as defined in Rule 405 of the Act) that constitute an offer to sell or solicitation of an offer to buy the Notes (each such communication by the Issuers and
the Guarantors or each of their agents and representatives (other than the Pricing Disclosure Package and Final Memorandum), an “Issuer Written Communication”) other than the Pricing Disclosure Package, the Final Memorandum and the
recorded electronic road show made available to investors (the “Recorded Road Show”). Any information in an Issuer Written Communication that is not otherwise included in the Pricing Disclosure Package and the Final Memorandum does
not conflict with the Pricing Disclosure Package or the Final Memorandum and, each Issuer Written Communication, when taken together with the Pricing Disclosure Package does not at the Time of Execution and when taken together with the Final
Memorandum at the Closing Date will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. 
 (b) Each of the Partnership, the General Partner and the Material Subsidiaries has been duly organized or
formed and is validly existing as a limited partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction set forth opposite its name in Schedule 2 attached hereto, with full power and authority
to own or lease its properties and to conduct its business, in each case as described in the Offering Memorandum in all material respects. Each of the Partnership, the General Partner and the Material Subsidiaries is duly registered or qualified to
do business as a foreign limited partnership or limited liability company, as applicable, and is in good standing under the laws of each jurisdiction which requires such registration or qualification, except where the failure to be so registered or
qualified would not reasonably be expected to have a Material Adverse Effect. “Material Adverse Effect” 

  
 3 

 
shall mean a material adverse effect on (i) the business or properties, earnings, condition (financial or otherwise) or prospects, taken as a whole, of the Partnership and its Subsidiaries,
considered as one enterprise, whether or not in the ordinary course of business, or (ii) the ability of each Issuer and each Guarantor to perform its obligations under the Notes. 

(c) Finance Co has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State
of Delaware. 
 (d) The General Partner is the sole general partner of the Partnership with an approximate 2.0% general
partner interest in the Partnership, taking into account the general partner interests which will be issued on or before a record date, end of a month or end of a quarter pursuant to Section 5.2(c) of the agreement of limited partnership of the
Partnership (as the same has been amended or restated, the “Partnership Agreement”); such general partner interest has been duly and validly authorized and issued in accordance with the Partnership Agreement; and the General Partner
owns such general partner interest free and clear of all liens, encumbrances, security interests, charges or other claims (“Liens”) other than (i) those created by or arising under the Delaware Revised Uniform Limited
Partnership Act (the “Delaware LP Act”) or the Partnership Agreement, (ii) restrictions on transferability and other Liens described in the Offering Memorandum, (iii) those arising pursuant to or permitted under that
certain Fourth Amended and Restated Credit Agreement, dated June 29, 2018, by and among the Partnership, Bank of America, N.A., as Administrative Agent, Collateral Agent and Swing Line Lender, and the other lenders and L/C Issuers party thereto
(as supplemented, amended or restated and, together with the agreements, exhibits, and attachments contemplated or included therein, the “Partnership Credit Agreement”), or (iv) those
arising pursuant to or permitted under that certain Credit Agreement, dated February 27, 2015, by and among Targa Resources Corp., Bank of America, N.A. as Administrative Agent, Collateral Agent, Swing Line Lender and the L/C Issuer and each
lender from time to time party thereto, as amended. 
 (e) All of the issued and outstanding equity interests of each
Material Subsidiary (i) have been duly authorized and validly issued (in accordance with the limited partnership or limited liability company agreement (collectively, the “Organizational Agreements”) or the certificate of
limited partnership, formation or conversion or other similar organizational document (in each case as in effect on the date hereof and as the same has been amended or restated) (collectively with the Organizational Agreements, the “Material
Subsidiary Organizational Documents”), as applicable, of such Material Subsidiary), are fully paid (except in the case of an interest in a limited partnership or limited liability company, to the extent required under the organizational
documents of such Material Subsidiary) and nonassessable (except as such nonassessability may be affected by Sections 17-607 and 17-804 of the Delaware LP Act, Sections 18-607 and 18-804 of the Delaware Limited Liability Company Act (the “Delaware LLC Act”) or Sections 153.102, 153.103, 153.202 and 153.210 of the Texas
Business Organizations Code (“TBOC”), as applicable), other than equity interests that are not owned, directly or indirectly, by the Partnership, and (ii) other than Cedar Bayou Fractionators, L.P., a Delaware limited
partnership (“CBF”), Targa Pipeline Mid-

  
 4 

 
Continent WestOk LLC, a Delaware limited liability company (“WestOk”), Targa Pipeline Mid-Continent WestTex LLC, a Delaware limited
liability company (“WestTex”), Carnero G&P LLC, a Delaware limited liability company (“Carnero”), Centrahoma Processing LLC, a Delaware limited liability company (“Centrahoma”), Grand Prix
Pipeline LLC, a Delaware limited liability company (“Grand Prix”), Targa Badlands LLC (“Badlands”) and Venice Energy Services Company, L.L.C. (“VESCO”) are owned, directly or indirectly, by the
Partnership, free and clear of all Liens, other than those arising pursuant to or permitted under the Partnership Credit Agreement and the applicable Material Subsidiary Organizational Documents. The Partnership owns, directly or indirectly,
(A) an 88.24% interest in CBF, (B) all of the outstanding Class B Units in WestOk, (C) all of the outstanding Class B Units in WestTex, (D) a 50.0% interest in Carnero, (E) a 60.0% interest in Centrahoma,
(F) a 56.0% interest in Grand Prix, (G) a 55.0% interest in Badlands and (H) a 76.7536% interest in VESCO, in each case free and clear of all Liens except those arising pursuant to or permitted under the Partnership Credit Agreement
and the applicable Material Subsidiary Organizational Documents. The Subsidiaries other than the Subsidiaries listed on Schedule 5 hereto did not, individually or in the aggregate, account for (x) more than 10% of the total assets of the
Partnership and the Subsidiaries, taken as a whole, as of June 30, 2020 or (y) more than 10% of the net income of the Partnership and the Subsidiaries, taken as a whole, for the six months ended June 30, 2020. 

(f) The authorized, issued and outstanding equity interests of the Partnership are as set forth in the Offering Memorandum as
of the dates specified therein. All of the issued equity interests of the Partnership and all of the issued shares of capital stock of Finance Co have been duly authorized and validly issued and are fully paid (to the extent required in the
Partnership Agreement with respect to the Partnership) and nonassessable (except as such nonassessability may be affected by Sections 17-607 and 17-804 of the Delaware
LP Act with respect to the Partnership); and none of the outstanding equity interests of the Partnership and none of the outstanding shares of capital stock of Finance Co were issued in violation of the preemptive or other similar rights of any
security holder of the Partnership or Finance Co, respectively. 
 (g) Except as otherwise disclosed in the Offering
Memorandum, there are no outstanding (i) securities or obligations of the Partnership convertible into or exchangeable for any equity interests of the Partnership, (ii) warrants, rights or options to subscribe for or purchase from the
Partnership any such equity interests or any such convertible or exchangeable securities or obligations or (iii) obligations of the Partnership to issue any such equity interests, any such convertible or exchangeable securities or obligations,
or any such warrants, rights or options. 
 (h) Each of the Issuers and each Guarantor has all requisite corporate,
partnership or limited liability company power and authority, as applicable, to execute, deliver and perform each of its obligations under the Notes, the Exchange Notes and the Private Exchange Notes (as defined in the Registration Rights
Agreement). The Notes, the Exchange Notes and the Private Exchange Notes have each been duly authorized by the Issuers and, when executed by each of the Issuers and authenticated by the Trustee in accordance with the provisions of the Indenture and,
in the case of the Notes, when 

  
 5 

 
delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, and, in the case of any Exchange Notes or Private Exchange Notes, when issued in exchange for
the Notes as provided in the Registration Rights Agreement, will constitute valid and legally binding obligations of each of the Issuers, entitled to the benefits of the Indenture, and enforceable against each of the Issuers in accordance with their
terms, except that the enforcement thereof may be subject to (i) bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect relating to creditors’ rights generally, and (ii) general principles
of equity and the discretion of the court before which any proceeding therefor may be brought (collectively, the “Enforceability Exceptions”). The Guarantees have been duly authorized by each Guarantor and, upon the due issuance and
delivery of the related Notes and the due endorsement of the notations of Guarantee thereon, will constitute valid and legally binding obligations of each Guarantor, enforceable against each Guarantor in accordance with their terms, except that the
enforcement thereof may be subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. 

(i) Each of the Issuers and each Guarantor has all requisite corporate, partnership or limited liability company power and
authority, as applicable, to execute, deliver and perform each of its obligations under the Indenture. The Indenture meets the requirements for qualification under the Trust Indenture Act of 1939, as amended (the “TIA”). The
Indenture has been duly authorized by each of the Issuers and Guarantors and, when executed and delivered by each of the Issuers and each Guarantor (assuming the due authorization, execution and delivery by the Trustee), will constitute a valid and
legally binding agreement of each of the Issuers and each Guarantor, enforceable against each of the Issuers and each Guarantor in accordance with its terms, except that the enforcement thereof may be subject to the Enforceability Exceptions. 

(j) Each of the Issuers and each Guarantor has all requisite corporate, partnership or limited liability company power and
authority, as applicable, to execute, deliver and perform each of its obligations under the Registration Rights Agreement. The Registration Rights Agreement has been duly authorized by the Issuers and the Guarantors and, when executed and delivered
by each of the Issuers and each Guarantor (assuming the due authorization, execution and delivery by the Initial Purchasers), will constitute a valid and legally binding agreement of each of the Issuers and each Guarantor, enforceable against each
of the Issuers and each Guarantor in accordance with its terms, except that (A) the enforcement thereof may be subject to the Enforceability Exceptions and (B) any rights to indemnity or contribution thereunder may be limited by federal
and state securities laws and public policy considerations. 
 (k) Each of the Issuers and each Guarantor has all requisite
corporate, partnership or limited liability company power and authority, as applicable, to execute, deliver and perform each of its obligations under this Agreement and to consummate the transactions contemplated hereby. This Agreement and the
consummation by each of the Issuers and each Guarantor of the transactions contemplated hereby have been duly authorized by each of the Issuers and each Guarantor. This Agreement has been duly executed and delivered by each of the Issuers and each
Guarantor. 

  
 6 

 (l) No permit, consent, approval, authorization, order, registration, filing
or qualification (“Permits”) of or with any court or governmental agency or body having jurisdiction over any of the Issuers or any Material Subsidiary or any of their respective properties or assets is required in connection with
the issuance and sale by the Issuers of the Notes to the Initial Purchasers or the consummation by the Issuers of the other transactions contemplated hereby, except (i) such Permits as may be required under the Act, the Exchange Act and state
securities or “Blue Sky” laws of any jurisdiction, (ii) such Permits as have been obtained or will be obtained prior to the Closing Date, (iii) such Permits that, if not obtained, could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect and (iv) such Permits as are disclosed in the Offering Memorandum. 

(m) Neither of the Issuers nor any Material Subsidiary is in (i) violation of its organizational documents,
(ii) violation of any statute, law, rule or regulation, or any judgment, order, injunction or decree of any court, governmental agency or body or arbitrator having jurisdiction over any of the Issuers or Material Subsidiaries or any of their
respective properties or assets or (iii) breach, default (or an event which, with notice or lapse of time or both, would constitute such an event) or violation in the performance of any obligation, agreement or condition contained in any
indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, which in the case of either clause (ii) or (iii) would, if continued, have a
Material Adverse Effect. 
 (n) None of (i) the execution, delivery and performance by either of the Issuers or any
Guarantor of this Agreement, the Indenture and the Registration Rights Agreement or (ii) the consummation by either of the Issuers or any Guarantor of the transactions contemplated hereby (including, without limitation, the issuance and sale of
the Notes to the Initial Purchasers) (A) constitutes or will constitute a violation of the organizational documents of either of the Issuers or any Guarantor, (B) conflicts or will conflict with or constitutes or will constitute a breach
or violation of, or a default (or an event that, with notice or lapse of time or both, would constitute such a default) under any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which either of the
Issuers or any Guarantor is a party or by which any of them or any of their respective properties may be bound, or (C) (assuming compliance with all applicable state securities or “Blue Sky” laws and assuming the accuracy of the
representations and warranties of the Initial Purchasers in Section 8 hereof) violates or will violate any statute, judgment, decree, order, rule or regulation applicable to either of the Issuers or any Guarantor or any of their respective
properties or assets, except, with respect to clauses (B) and (C) only, for any such breach or violation that would not, individually or in the aggregate, have a Material Adverse Effect or materially impair the ability of the Issuers or the
Guarantors, as applicable, to consummate the transactions contemplated by this Agreement. 
 (o) The Partnership Agreement
has been duly authorized, executed and delivered by the General Partner, and is a valid and legally binding agreement of the General Partner, enforceable against the General Partner in accordance with its terms; provided, that, with respect
to the Partnership Agreement, the enforceability thereof may 

  
 7 

 
be limited by the Enforceability Exceptions; provided, further, that the indemnity, contribution and exoneration provisions contained in any of such agreements may be limited by
applicable laws and public policy. 
 (p) The Organizational Agreements of the Material Subsidiaries, as applicable, have
been duly authorized, executed and delivered by the parties thereto that are affiliates of the Partnership, and are valid and legally binding agreements of such parties, enforceable against such parties in accordance with their terms;
provided, that, with respect to such agreements, the enforceability thereof may be limited by the Enforceability Exceptions; provided, further, that the indemnity, contribution and exoneration provisions contained in any of such
agreements may be limited by applicable laws and public policy. 
 (q) The historical consolidated financial statements of
the Partnership and its Subsidiaries included in the Offering Memorandum present fairly in all material respects the financial position, results of operations and cash flows of the Partnership and its consolidated Subsidiaries purported to be shown
thereby on the basis stated therein at the respective dates or for the respective periods to which they apply, and have been prepared in accordance with generally accepted accounting principles consistently applied throughout the periods involved,
except to the extent disclosed therein. PricewaterhouseCoopers LLP (the “Independent Accountants”), which has certified certain financial statements of the Partnership and its Subsidiaries and delivered its report with respect to
the audited consolidated financial statements incorporated by reference in the Offering Memorandum, is an independent public accounting firm within the meaning of the Act and the rules and regulations promulgated thereunder. The interactive data in
eXtensbile Business Reporting Language included or incorporated by reference in the Pricing Disclosure Package and the Final Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the
Commission’s rules and guidelines applicable thereto in all material respects. 
 (r) Except as set forth or
contemplated in the Offering Memorandum, there is (i) no action, suit or proceeding before or by any court, arbitrator or governmental agency, body or official, domestic or foreign, now pending or, to the knowledge of the Partnership,
threatened, to which any of the Issuers or Material Subsidiaries is or may be a party or to which the business or property of any of the Issuers or Material Subsidiaries is or may be subject, (ii) to the knowledge of the Partnership, no
statute, rule, regulation or order that has been enacted, adopted or issued by any governmental agency and (iii) no injunction, restraining order or order of any nature issued by a federal or state court or foreign court of competent
jurisdiction to which any of the Issuers or Material Subsidiaries is or may be subject, that, in the case of clauses (i), (ii) and (iii) above, is reasonably expected to (A) individually or in the aggregate have a Material Adverse Effect,
(B) prevent the consummation of the issuance or sale of the Notes to be sold hereunder, or (C) draw into question the validity of this Agreement. 

(s) Each of the Issuers and the Material Subsidiaries possesses such permits, licenses, approvals, consents and other
authorizations (collectively, “Governmental Licenses”) issued by the appropriate federal, state, local or foreign regulatory agencies or 

  
 8 

 
bodies necessary to conduct their respective businesses, except where the failure so to possess would not, individually or in the aggregate, result in a Material Adverse Effect; each of the
Issuers and each Material Subsidiary is in compliance with the terms and conditions of all such Governmental Licenses, except where the failure so to comply would not, individually or in the aggregate, result in a Material Adverse Effect; all of the
Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, individually or in the aggregate, result in
a Material Adverse Effect; and except as described in the Offering Memorandum, neither of the Issuers and no Material Subsidiary has received any notice of proceedings relating to the revocation or modification of any such Governmental Licenses
which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect. 

(t) Since the date of the most recent financial statements appearing in the Offering Memorandum and except as set forth or
contemplated in the Offering Memorandum, (i) none of the Issuers or the Material Subsidiaries has incurred any liabilities or obligations, direct or contingent, or entered into or agreed to enter into any transactions or contracts (written or
oral) not in the ordinary course of business, which liabilities, obligations, transactions or contracts would, individually or in the aggregate, be material to the general affairs, management, business, condition (financial or otherwise), prospects
or results of operations of the Partnership and its Subsidiaries, taken as a whole and (ii) the Partnership has not purchased any of its outstanding equity interests, nor declared, paid or otherwise made any distribution of any kind on its
equity interests (other than (A) the Partnership’s quarterly or monthly distributions on its common units and the Partnership’s monthly distributions on its Series A
Fixed-to-Floating Rate Cumulative Redeemable Preferred Units, (B) with respect to any of the Subsidiaries, the purchase of, or dividend or distribution on, capital
stock or equity interests owned by the Partnership and (C) distribution equivalent rights on any of the Partnership’s equity-based awards). 

(u) Except as set forth or contemplated in the Offering Memorandum, each of the Issuers and the Material Subsidiaries has filed
all foreign, federal, state and local tax returns that are required to be filed or has requested extensions thereof, except in any case in which the failure so to file, individually or in the aggregate, would not have a Material Adverse Effect, and
has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such tax, assessment, fine or penalty that is currently being
contested in good faith or as, individually or in the aggregate, would not have a Material Adverse Effect. 
 (v) Immediately
after the consummation of the transactions contemplated by this Agreement, the fair value and present fair saleable value of the assets of each of the Issuers and the Material Subsidiaries (each on a consolidated basis) will exceed the sum of its
stated liabilities and identified contingent liabilities. Each of the Issuers and the Guarantors is not now nor, after giving effect to the issuance of the Notes and the execution, delivery and performance of this Agreement, the Registration Rights

  
 9 

 
Agreement and the Indenture and the consummation of the transactions contemplated thereby or described in the Offering Memorandum, will be (i) insolvent, (ii) left with unreasonably
small capital with which to engage in its anticipated business or (iii) incurring debts or other obligations beyond its ability to pay such debts or obligations as they become due. 

(w) Any statistical and market-related data included in the Offering Memorandum are based on or derived from sources that each
of the Issuers and the Guarantors believe to be reliable and accurate, and the Issuers have obtained the written consent to the use of such data from such sources to the extent required. 

(x) Each of the Issuers and the Material Subsidiaries has good and marketable title to all real property and good title to all
personal property described in the Offering Memorandum as being owned by it free and clear of all Liens, except (i) as described, and subject to limitations contained, in the Offering Memorandum, (ii) Liens that arise under the Partnership
Credit Agreement or (iii) to the extent the failure to have such title or the existence of such Liens would not, individually or in the aggregate, have a Material Adverse Effect; provided that, with respect to any real property and
buildings held under lease by the Partnership and the Material Subsidiaries, such real property and buildings are held under valid and subsisting and enforceable leases with such exceptions as do not materially interfere with the use of the
properties of the Partnership and the Material Subsidiaries taken as a whole as they have been used in the past as described in the Offering Memorandum and are proposed to be used in the future as described in the Offering Memorandum, except to the
extent the failure to hold such valid and subsisting and enforceable leases would not, individually or in the aggregate, have a Material Adverse Effect. 

(y) The Partnership and the Material Subsidiaries have such easements or rights-of-way (collectively, “rights-of-way”) as are necessary to conduct their business in the manner
described, and subject to the limitations contained, in the Offering Memorandum, except for (i) qualifications, reservations and encumbrances that would not have, individually or in the aggregate, a Material Adverse Effect, (ii) such rights-of-way that, if not obtained, would not have, individually or in the aggregate, a Material Adverse Effect and (iii) rights-of-way held by affiliates of the Partnership as nominee for the benefit of the Partnership and the Material Subsidiaries. 

(z) Except for such exceptions that would not reasonably be expected to result in a Material Adverse Effect, (i) each of
the Issuers and each Material Subsidiary owns or possesses, or can acquire or use on reasonable terms, adequate patents, patents rights, licenses, inventions, copyrights, know-how (including trade secrets and
other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, “Intellectual Property”) necessary to carry
out their respective businesses now or proposed to be operated by them as described in the Offering Memorandum, and (ii) each of the Issuers and each Material Subsidiary has not received any notice and is not otherwise aware of any infringement
of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances that would render any Intellectual Property invalid or inadequate to protect any of its interest therein. 

  
 10 

 (aa) There are no legal or governmental proceedings pending or, to the
knowledge of the Partnership, threatened or contemplated, against either of the Issuers or the Material Subsidiaries or any of their respective properties or assets that would be required to be described in a prospectus pursuant to the Act that are
not described in the Offering Memorandum, nor are there any agreements, contracts, indentures, leases or other instruments that would be required to be described in a prospectus pursuant to the Act that are not described in the Offering Memorandum.
Except as set forth or contemplated in the Offering Memorandum, to the knowledge of the Partnership, no legal or governmental proceedings are pending or threatened to which either of the Issuers or any of the Material Subsidiaries is a party or to
which the property or assets of the Issuers or any Material Subsidiary is subject that, if determined adversely to the Issuers or the Material Subsidiaries, could be reasonably expected to result, individually or in the aggregate, in a Material
Adverse Effect. 
 (bb) The Partnership is in compliance in all material respects with all applicable provisions of the
Sarbanes Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the “Sarbanes Oxley Act”). 

(cc) Except as disclosed in the Offering Memorandum or as would not, individually or in the aggregate, result in a Material
Adverse Effect: (i) the Partnership and the Material Subsidiaries are and, during the relevant time periods specified in all applicable statutes of limitation, have been in compliance with applicable Environmental Laws (as defined below); (ii)
the Partnership and the Material Subsidiaries have obtained and are in compliance with all Environmental Permits (as defined below) required of them under applicable Environmental Laws to conduct the Partnership’s business as presently
conducted; (iii) none of the Partnership or the Material Subsidiaries has received any written notice of an action, suit, demand, claim, hearing, notice of violation or investigation, or proceeding, which matter remains unresolved and alleges
liability of the Partnership or any Material Subsidiary under, or violation by the Partnership or any Material Subsidiary of, any Environmental Law, and to the knowledge of the Partnership, no facts, circumstances or conditions exist that would
reasonably be expected to result in the receipt of such notice; and (iv) to the knowledge of the Partnership, there are no releases of Hazardous Materials (as defined below) that would reasonably be expected to give rise to liabilities or
obligations under any Environmental Law. 
 For purposes of this Agreement: (i) “Environmental Law” means all federal, state
and local laws, rules (including but not limited to rules of common law), regulations, ordinances, orders, decrees and other legally-enforceable requirements of any governmental entity relating to pollution, protection of human health (to the extent
relating to exposure to Hazardous Materials) or the Environment, including those relating to the generation, storage, treatment, disposal, transport or release of Hazardous Materials; (ii) “Hazardous Materials” means any pollutant
or contaminant, chemical, material, waste or substance in any form regulated under any applicable Environmental Law including, but not limited to any: (A) “hazardous substance” as defined in the

  
 11 

 
Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended; (B) “hazardous waste” as defined in the Resource Conservation and Recovery Act, as
amended; (C) petroleum or petroleum product, natural gas, natural gas liquids, or crude oil or any fraction thereof; (D) polychlorinated biphenyls; and (E) naturally occurring radioactive materials; (iii) “Environmental
Permits” means any permit, authorization, license, variance, and approvals required under applicable Environmental Law; and (iv) “Environment” means ambient air, indoor air, surface water, groundwater, drinking water, land
surface and subsurface strata, and natural resources such as wetlands, flora and fauna. 
 (dd) There is no strike, labor
dispute, slowdown or work stoppage with the employees of the Issuers or the Material Subsidiaries that is pending or, to the knowledge of the Partnership, threatened that could reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect. 
 (ee) Except as disclosed in the Offering Memorandum, no proceedings for the merger,
consolidation, liquidation or dissolution of either of the Issuers or the Material Subsidiaries or the sale of all or a material part of the assets of either of the Issuers or the Material Subsidiaries or any material acquisition by either of the
Issuers or any Material Subsidiary are pending that would be required by the Act to be disclosed in a prospectus included in a Registration Statement on Form S-1 under the Act. 

(ff) (i) The Issuers and the Material Subsidiaries have not sustained, since the date of the latest audited financial
statements included in the Offering Memorandum (exclusive of any amendment or supplement thereto), any material loss or interference with its business or properties from fire, explosion, flood, accident or other calamity, whether or not covered by
insurance, or from any labor dispute or court or governmental action, order or decree (whether domestic or foreign) otherwise than as set forth in the Offering Memorandum (exclusive of any amendment or supplement thereto) and (ii) since such
date, there has not occurred any change or development which could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

(gg) Each of the Issuers and the Material Subsidiaries carries or is entitled to the benefits of insurance relating to their
assets, with financially sound and reputable insurers, in such amounts and covering such risks as is commercially reasonable, and all such insurance is in full force and effect. Each of the Issuers and the Material Subsidiaries has no reason to
believe that it will not be able (i) to renew their existing insurance coverage relating to their respective assets as and when such policies expire or (ii) to obtain comparable coverage relating to their respective assets from similar
institutions as may be necessary or appropriate to conduct such business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect. 

(hh) Except (i) as disclosed in the Offering Memorandum and (ii) in regard to regulation by the Federal Energy
Regulation Commission, neither of the Issuers nor any Material Subsidiary is subject to rate regulation under federal law. 

  
 12 

 (ii) Except as would not, individually or in the aggregate, have a Material
Adverse Effect, (i) each of the Issuers and each Material Subsidiary is in compliance with its obligations under all presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations
and published interpretations thereunder (“ERISA”); with respect to each “plan” (as defined in Section 3(3) of ERISA) in which any current or former employees of the Partnership or of any trade or business that,
together with the Partnership, is or has been treated, within the six years preceding such date, as a single employer under Section 4001(b)(1) of ERISA or Section 414 of the Internal Revenue Code of 1986, as amended, including the
regulations and published interpretations thereunder (the “Code”), are or have been eligible to participate, (ii) no “reportable event” (as defined in ERISA) has occurred with respect to any such plan that is a
“pension plan” (as defined in ERISA, hereinafter, a “Pension Plan”) for which any of the Issuers or a Material Subsidiary would have any liability, excluding any reportable event for which a waiver could apply; and
(iii) none of the Issuers or Material Subsidiaries expects to incur liability under Title IV of ERISA with respect to termination of, or withdrawal from, any Pension Plan or Sections 430 or 4971 of the Code with respect to any Pension Plan.

 (jj) Except as disclosed in the Offering Memorandum, the Partnership and the Material Subsidiaries maintain a system of
internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific
authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Offering Memorandum, the
Partnership’s and the Material Subsidiaries’ internal controls over financial reporting are effective and none of the Partnership and the Material Subsidiaries is aware of any material weakness in their internal control over financial
reporting. 
 (kk) Except as disclosed in the Offering Memorandum, (i) the Partnership has established and maintains
disclosure controls and procedures (to the extent required by and as such term is defined in Rule 13a-15 under the Exchange Act), (ii) such disclosure controls and procedures are designed to ensure that the
information required to be disclosed by the Partnership in the reports filed or to be filed or submitted under the Exchange Act, as applicable, is accumulated and communicated to management of the General Partner, including its principal executive
officers and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure to be made and (iii) such disclosure controls and procedures are effective in all material respects to perform the functions for
which they were established to the extent required by Rule 13a-15 of the Exchange Act. 

(ll) Neither of the Issuers nor any Guarantor is an “investment company” or “promoter” or “principal
underwriter” for an “investment company,” as such terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”), and the rules and regulations thereunder. 

  
 13 

 (mm) The descriptions of the Notes, the Indenture and the Registration
Rights Agreement contained in the Offering Memorandum are accurate in all material respects. 
 (nn) No holder of securities
of either of the Issuers or the Material Subsidiaries will be entitled to have such securities registered under the registration statements that may be required to be filed by the Issuers pursuant to the Registration Rights Agreement other than as
expressly permitted in the Registration Rights Agreement. 
 (oo) None of the Issuers, any Material Subsidiary or, to the
knowledge of the Issuers, any of their respective Affiliates (as defined in Rule 501(b) of Regulation D under the Act) has directly, or through any agent, (i) sold, offered for sale, solicited offers to buy or otherwise negotiated in
respect of, any “security” (as defined in the Act) that is or could be integrated with the sale of the Notes in a manner that would require the registration under the Act of the Notes or (ii) engaged in any form of general
solicitation or general advertising (as those terms are used in Regulation D under the Act) in connection with the offering of the Notes or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Act. Assuming the
accuracy of the representations and warranties of the Initial Purchasers in Section 8 hereof, it is not necessary in connection with the offer, sale and delivery of the Notes to the Initial Purchasers or the endorsement of the Guarantees by the
Guarantors in the manner contemplated by this Agreement to register any of the Notes under the Act or to qualify the Indenture under the TIA. 

(pp) No securities of either of the Issuers or the Guarantors are of the same class (within the meaning of Rule 144A under
the Act) as the Notes and listed on a national securities exchange registered under Section 6 of the Exchange Act, or quoted in a U.S. automated inter-dealer quotation system. 

(qq) None of the Issuers or the Material Subsidiaries has taken, nor will any of them take, directly or indirectly, any action
designed to, or that would constitute or that might be reasonably expected to result in, stabilization or manipulation of the price of the Notes. 

(rr) None of the Issuers, the Material Subsidiaries or, to the knowledge of the Issuers, any of their respective Affiliates or
any person acting on its or their behalf (other than the Initial Purchasers) has engaged in any directed selling efforts (as that term is defined in Regulation S under the Act (“Regulation S”)) with respect to the Notes; the
Issuers, the Material Subsidiaries and, to the knowledge of the Issuers, their respective Affiliates and any person acting on its or their behalf (other than the Initial Purchasers) have complied with the offering restrictions requirement of
Regulation S. 
 (ss) There are no stamp or other issuance or transfer taxes or duties or other similar fees or charges
required to be paid in the United States in connection with the execution and delivery of this Agreement or the issuance or sale by the Issuers of the Notes. 

  
 14 

 (tt) None of the Issuers, the Subsidiaries or, to the knowledge of the
Issuers, any director, officer, agent, employee or Affiliate of the Issuers or any of the Subsidiaries (in their capacity as directors, officers, agents or employees) is aware of or has taken any action, directly or indirectly, that would result in
a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of
interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign
official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA; and the Issuers, the Subsidiaries and, to the knowledge of the
Issuers, their affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith. 
 (uu) The operations of the Issuers and the Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the USA PATRIOT Act, the rules and regulations
thereunder, and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator involving the Issuers or any of the Subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Issuers, threatened. 

(vv) No Material Subsidiary is currently prohibited, directly or indirectly, from paying any distributions to the Partnership,
from making any other distribution on such Material Subsidiary’s equity interests, from repaying to the Partnership any loans or advances to such Material Subsidiary from the Partnership or from transferring any of such Material
Subsidiary’s property or assets to the Partnership or any other Subsidiary of the Partnership, except (i) as described in or contemplated by the Offering Memorandum, (ii) arising pursuant to or permitted under the Partnership Credit
Agreement, (iii) such prohibitions mandated by the laws of each such Material Subsidiary’s state of formation or the terms of any such Material Subsidiary’s governing instruments or (iv) where such prohibition would not
reasonably be expected to have a Material Adverse Effect. 
 (ww) None of the Issuers, the Subsidiaries or, to the knowledge
of the Issuers, any director, officer, agent, employee or Affiliate of the Issuers or any of the Subsidiaries (in their capacity as directors, officers, agents or employees) is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) nor is either Issuer or the Subsidiaries located, 

  
 15 

 
organized or resident in a country or territory that is the subject or target of U.S. sanctions; and the Issuers will not directly or indirectly use the proceeds of the offering, or lend,
contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing or facilitating the activities of any person currently subject to any U.S. sanctions administered
by OFAC or in any sanctioned country. 
 Any certificate signed by any officer of the Issuers or the Guarantors and delivered to any Initial
Purchaser or to counsel for the Initial Purchasers in connection with the offering of the Notes shall be deemed a representation and warranty by each of the Issuers or each Guarantor to the Initial Purchasers as to the matters covered thereby. 

Section 3. Purchase, Sale and Delivery of the Notes. On the basis of the representations, warranties, agreements and covenants
herein contained and subject to the terms and conditions herein set forth, the Issuers agree to issue and sell to the Initial Purchasers, and the Initial Purchasers, acting severally and not jointly, agree to purchase the Notes in the respective
amounts set forth on Schedule 1 hereto from the Issuers at 99.25% of their principal amount. One or more certificates in global form for the Notes that the Initial Purchasers have agreed to purchase hereunder, each in such principal amount as
the Initial Purchasers request upon notice to the Issuers at least 36 hours prior to the Closing Date, shall be delivered by or on behalf of the Issuers to the Trustee, as custodian for The Depository Trust Company (“DTC”), and the
Notes in book-entry form shall be delivered to the Initial Purchasers through the facilities of DTC, against payment by or on behalf of the Initial Purchasers of the purchase price therefor by wire transfer (same day funds), to such account or
accounts as the Partnership shall specify prior to the Closing Date, or by such means as the parties hereto shall agree prior to the Closing Date. Such delivery of the certificates and payment for the Notes shall be made at the offices of
Vinson & Elkins L.L.P., 1001 Fannin Street, Suite 2500, Houston, Texas at 9:00 A.M. Houston time, on August 18, 2020, or at such other place, time or date as the Initial Purchasers, on the one hand, and the Issuers, on the other hand, may
agree upon, such time and date of delivery against payment being herein referred to as the “Closing Date.” 

Section 4. Offering by the Initial Purchasers. The Initial Purchasers propose to make an offering of the Notes at the prices and
upon the terms set forth in the Pricing Disclosure Package and the Final Memorandum as soon as practicable after this Agreement is entered into and as in the judgment of the Initial Purchasers is advisable. 

Section 5. Covenants of the Issuers and the Guarantors. Each Issuer and each Guarantor covenants and agrees with each of the
Initial Purchasers as follows: 
 (a) Until the later of (i) the completion of the distribution of the Notes by the
Initial Purchasers and (ii) the Closing Date, the Issuers will not amend or supplement the Pricing Disclosure Package or the Final Memorandum or otherwise distribute or refer to any Issuer Written Communication (other than the Recorded Road
Show) unless the Initial Purchasers shall previously have been advised and furnished a copy for a reasonable period of time prior to the proposed amendment or supplement. The Issuers will promptly, upon the reasonable request of the Initial
Purchasers or counsel for the Initial Purchasers, make any amendments or supplements to the Pricing Disclosure Package and the Final Memorandum that may be necessary or advisable in connection with the resale of the Notes by the Initial Purchasers.

  
 16 

 (b) The Issuers will cooperate with the Initial Purchasers in arranging for
the qualification of the Notes for offering and sale under the securities or “Blue Sky” laws of such jurisdictions as the Initial Purchasers may designate and will continue such qualifications in effect for as long as may be necessary to
complete the resale of the Notes; provided, however, that in connection therewith, the Issuers shall not be required to qualify as a foreign limited partnership or corporation or to execute a general consent to service of process in
any jurisdiction or subject itself to taxation in any such jurisdiction where it is not then so subject. 
 (c) (1) If, at
any time prior to the completion of the sale by the Initial Purchasers of the Notes, any event occurs or information becomes known as a result of which the Final Memorandum as then amended or supplemented would include any untrue statement of a
material fact, or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or if for any other reason it is necessary at any time to amend or supplement the
Final Memorandum to comply with applicable law, the Issuers will promptly notify the Initial Purchasers thereof and will prepare, at the expense of the Partnership, an amendment or supplement to the Final Memorandum that corrects such statement or
omission or effects such compliance and (2) if at any time prior to the Closing Date (i) any event shall occur or condition shall exist as a result of which any of the Pricing Disclosure Package as then amended or supplemented would
include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or any Issuer Written Communication
would conflict with the Pricing Disclosure Package as then amended or supplemented, or (ii) it is necessary to amend or supplement any of the Pricing Disclosure Package so that any of the Pricing Disclosure Package or any Issuer Written
Communication will comply with law, the Issuers will immediately notify the Initial Purchasers thereof and forthwith prepare and, subject to paragraph (a) above, furnish to the Initial Purchasers such amendments or supplements to any of the
Pricing Disclosure Package or any Issuer Written Communication (it being understood that any such amendments or supplements may take the form of an amended or supplemented Final Memorandum) as may be necessary so that the statements in any of the
Pricing Disclosure Package as so amended or supplemented will not, in light of the circumstances under which they were made, be misleading or so that any Issuer Written Communication will not conflict with the Pricing Disclosure Package or so that
the Pricing Disclosure Package or any Issuer Written Communication as so amended or supplemented will comply with law. 
 (d)
The Issuers will, without charge, provide to the Initial Purchasers and to counsel for the Initial Purchasers as many copies of the Pricing Disclosure Package, any Issuer Written Communication and the Final Memorandum or any amendment or supplement
thereto as the Initial Purchasers may reasonably request. 

  
 17 

 (e) The Partnership will apply the net proceeds from the sale of the Notes
as set forth under “Use of Proceeds” in the Pricing Disclosure Package and the Final Memorandum. 
 (f) Prior to
the Closing Date, the Issuers will furnish to the Initial Purchasers, as soon as they have been prepared, a copy of any unaudited interim financial statements of the Issuers for any period subsequent to the period covered by the most recent
financial statements appearing in the Pricing Disclosure Package and the Final Memorandum; provided, however, that the Issuers do not need to furnish such financial statements to the Initial Purchasers if they are available on the
Commission’s website. 
 (g) None of the Issuers or any of their affiliates that they control will, and the Issuers will
use their commercially reasonable efforts to cause their other affiliates not to, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any “security” (as defined in the Act) that could be integrated with the
sale of the Notes in a manner which would require the registration under the Act of the Notes. 
 (h) The Issuers will not,
and will not permit any of their subsidiaries or their respective affiliates that they control or persons acting on their behalf to, and the Issuers will use their commercially reasonable efforts to cause their other affiliates not to, engage in any
form of general solicitation or general advertising (as those terms are used in Regulation D under the Act) in connection with the offering of the Notes or in any manner involving a public offering within the meaning of Section 4(a)(2) of the
Act. 
 (i) For so long as any of the Notes remain outstanding, the Issuers or Targa Resources Corp. will make available at
their expense, upon request, to any holder of the Notes and any prospective purchasers thereof the information specified in Rule 144A(d)(4) under the Act, unless either of the Issuers or Targa Resources Corp. is then subject to Section 13
or 15(d) of the Exchange Act. 
 (j) The Issuers will use their commercially reasonable efforts to permit the Notes to be
eligible for clearance and settlement through DTC. 
 (k) During the period beginning on the date hereof and continuing to
the date that is 45 days after the Closing Date, without the prior written consent of the Representative, the Issuers will not offer, sell, contract to sell or otherwise dispose of, except as provided hereunder, any securities of the Issuers (or
guaranteed by the Issuers) that are substantially similar to the Notes (except for the Exchange Notes which would be issuable pursuant to the exchange offer described in the Preliminary Memorandum and the Final Memorandum). 

(l) In connection with Notes offered and sold in an offshore transaction (as defined in Regulation S) the Issuers will not
register any transfer of the Notes not made in accordance with the provisions of Regulation S and will not, except in accordance with the provisions of Regulation S, if applicable, issue any such Notes in the form of definitive securities. 

  
 18 

 (m) None of the Issuers or any of their affiliates that they control will
engage in any directed selling efforts (as that term is defined in Regulation S) with respect to the Notes. 
 (n) For a
period of one year (calculated in accordance with paragraph (d) of Rule 144 under the Act) following the date any Notes are acquired by either of the Issuers or any of their affiliates, if the Notes are Registrable Securities (as defined
in the Registration Rights Agreement), neither of the Issuers nor any of their respective affiliates that they control will sell any such Notes. 

(o) For so long as any Notes are outstanding, the Issuers and the Guarantors will conduct their operations in a manner that
will not subject the Issuers or any Guarantor to registration as an investment company under the Investment Company Act. 

(p) Each Note will bear a legend substantially to the following effect until such legend shall no longer be necessary or
advisable because the Notes are no longer subject to the restrictions on transfer described therein: 
 “THIS SECURITY HAS NOT BEEN
REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH BELOW. BY
ITS ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS THAT (A) IT IS A “QUALIFIED INSTITUTIONAL BUYER” (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT), (B) IT IS NOT A U.S. PERSON AND IS ACQUIRING THIS SECURITY IN AN OFFSHORE
TRANSACTION IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT OR (C) IT IS AN ACCREDITED INVESTOR (AS DEFINED IN RULE 501(a)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT (AN “ACCREDITED INVESTOR”)), (2) AGREES THAT IT WILL
NOT WITHIN [IN THE CASE OF NOTES SOLD IN RELIANCE ON RULE 144A: ONE YEAR AFTER THE LATER OF THE ORIGINAL ISSUE DATE HEREOF AND THE LAST DATE ON WHICH AN ISSUER OR ANY AFFILIATE OF AN ISSUER WAS THE OWNER OF THIS SECURITY (OR ANY PREDECESSOR OF SUCH
SECURITY)] [IN THE CASE OF NOTES SOLD IN RELIANCE ON REGULATION S: 40 DAYS AFTER THE LATER OF THE ORIGINAL ISSUE DATE HEREOF AND THE DATE ON WHICH THIS SECURITY (OR ANY PREDECESSOR OF SUCH SECURITY) WAS FIRST OFFERED TO PERSONS OTHER THAN
DISTRIBUTORS (AS DEFINED IN RULE 902 OF REGULATION S)] (THE “RESALE RESTRICTION TERMINATION DATE”) RESELL OR OTHERWISE TRANSFER THIS SECURITY EXCEPT (A) TO AN ISSUER OR ANY SUBSIDIARY THEREOF, (B) INSIDE THE UNITED STATES TO A
QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, (C) INSIDE THE UNITED STATES TO AN ACCREDITED INVESTOR THAT, PRIOR TO SUCH TRANSFER, FURNISHES (OR HAS FURNISHED ON ITS BEHALF BY A U.S. BROKER-DEALER) TO THE
TRUSTEE A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS RELATING TO THE 

  
 19 

 
RESTRICTIONS ON TRANSFER OF THIS SECURITY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM THE TRUSTEE FOR THIS SECURITY), (D) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN COMPLIANCE
WITH RULE 904 UNDER THE SECURITIES ACT (IF AVAILABLE), (E) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE), (F) IN ACCORDANCE WITH ANOTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL IF THE COMPANY SO REQUESTS), OR (G) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND (3) AGREES THAT IT WILL GIVE TO EACH PERSON TO WHOM THIS SECURITY IS
TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN CONNECTION WITH ANY TRANSFER OF THIS SECURITY PRIOR TO THE RESALE RESTRICTION TERMINATION DATE, IF THE PROPOSED TRANSFEREE IS AN ACCREDITED INVESTOR, THE HOLDER MUST, PRIOR TO SUCH
TRANSFER, FURNISH TO THE TRUSTEE AND THE ISSUERS SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS ANY OF THEM MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION, NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, AS USED HEREIN. THE TERMS “OFFSHORE TRANSACTION,” “UNITED STATES” AND “U.S. PERSON” HAVE THE MEANING GIVEN TO THEM BY REGULATION S UNDER THE SECURITIES
ACT. THIS LEGEND WILL BE REMOVED UPON THE REQUEST OF THE HOLDER OR AN ISSUER ON OR AFTER THE RESALE RESTRICTION TERMINATION DATE.” 

Section 6. Expenses. The Partnership agrees to pay all costs and expenses incident to the performance of the Issuers’ and
Guarantors’ obligations under this Agreement, whether or not the transactions contemplated herein are consummated or this Agreement is terminated pursuant to Section 11 hereof, including all costs and expenses incident to (i) the
printing, word processing or other production of documents with respect to the transactions contemplated hereby, including any costs of printing the Pricing Disclosure Package and the Final Memorandum and any amendment or supplement thereto, and any
“Blue Sky” memoranda, (ii) all arrangements relating to the delivery to the Initial Purchasers of copies of the foregoing documents, (iii) the fees and disbursements of the counsel, the accountants and any other experts or
advisors retained by the Issuers, (iv) preparation (including printing), issuance and delivery to the Initial Purchasers of the Notes, (v) the qualification of the Notes under state securities and “Blue Sky” laws, including
filing fees and fees and disbursements of counsel for the Initial Purchasers relating thereto, (vi) one half of the expenses in connection with the “roadshow” and any other meetings with prospective investors in the Notes,
(vii) fees and expenses of the Trustee including fees and expenses of counsel, and (viii) any fees charged by investment rating agencies for the rating of the Notes. If the sale of the Notes provided for herein is not consummated because
any condition to the obligations of the Initial Purchasers set forth in Section 7 hereof is not satisfied, because this Agreement is terminated pursuant to Sections 11(a)(i), (ii) or (vi) or because of any failure, refusal or inability on
the part of the Issuers to perform all obligations and satisfy all conditions on their part to be performed or satisfied hereunder (other than solely by 

  
 20 

 
reason of a default by the Initial Purchasers of their obligations hereunder after all conditions hereunder have been satisfied in accordance herewith), the Issuers agree to promptly reimburse
the Initial Purchasers upon demand for all out-of-pocket expenses (including reasonable fees, disbursements and charges of Gibson, Dunn & Crutcher LLP, counsel
for the Initial Purchasers) that shall have been incurred by the Initial Purchasers in connection with the proposed purchase and sale of the Notes. 

Section 7. Conditions of the Initial Purchasers’ Obligations. The obligation of the Initial Purchasers to purchase and pay
for the Notes shall be subject to the satisfaction or waiver, in the sole discretion of the Representative, of the following conditions on or prior to the Closing Date: 

(a) On the Closing Date, the Initial Purchasers shall have received the opinion, dated as of the Closing Date and addressed to
the Initial Purchasers, of Vinson & Elkins L.L.P., counsel for the Issuers, in form and substance satisfactory to counsel for the Initial Purchasers, as to the matters described in Annex C hereto. 

(b) On the Closing Date, the Initial Purchasers shall have received the opinion, in form and substance satisfactory to the
Initial Purchasers, dated as of the Closing Date and addressed to the Initial Purchasers, of Gibson, Dunn & Crutcher LLP, counsel for the Initial Purchasers, with respect to certain legal matters relating to this Agreement and such other
related matters as the Initial Purchasers may reasonably require. In rendering such opinion, Gibson, Dunn & Crutcher LLP shall have received and may rely upon such certificates and other documents and information as it may reasonably
request to pass upon such matters. 
 (c) On the date hereof, the Initial Purchasers shall have received from the Independent
Accountants a comfort letter dated the date hereof, in form and substance satisfactory to counsel for the Initial Purchasers with respect to the audited and any unaudited financial information in the Pricing Disclosure Package. On the Closing Date,
the Initial Purchasers shall have received from the Independent Accountants a comfort letter dated the Closing Date, in form and substance satisfactory to counsel for the Initial Purchasers, which shall refer to the comfort letter dated the date
hereof and reaffirm or update as of a more recent date, the information stated in the comfort letter dated the date hereof and similarly address the audited and any unaudited financial information in the Final Memorandum. 

(d) The representations and warranties of the Issuers and the Guarantors contained in this Agreement shall be true and correct
on and as of the Time of Execution and on and as of the Closing Date as if made on and as of the Closing Date; the statements of the Issuers’ officers made pursuant to any certificate delivered in accordance with the provisions hereof shall be
true and correct on and as of the date made and on and as of the Closing Date; the Issuers shall have performed all covenants and agreements and satisfied all conditions on their part to be performed or satisfied hereunder at or prior to the Closing
Date; and, except as described in the Pricing Disclosure Package and the Final Memorandum (exclusive of any amendment or supplement thereto after the date hereof), subsequent to the date of the most recent

  
 21 

 
financial statements in such Pricing Disclosure Package and the Final Memorandum, there shall have been no event or development, and no information shall have become known, that, individually or
in the aggregate, has or would be reasonably likely to have a Material Adverse Effect. 
 (e) The sale of the Notes hereunder
shall not be enjoined (temporarily or permanently) on the Closing Date. 
 (f) Subsequent to the date of the most recent
financial statements in the Pricing Disclosure Package and the Final Memorandum (exclusive of any amendment or supplement thereto after the date hereof), none of the Issuers nor any of the Material Subsidiaries shall have sustained any loss or
interference with respect to its business or properties from fire, flood, hurricane, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute, slow down or work stoppage or from any legal or governmental
proceeding, order or decree, which loss or interference, individually or in the aggregate, has or would be reasonably likely to have a Material Adverse Effect. 

(g) The Initial Purchasers shall have received certificates, dated the Closing Date, signed by the Chief Executive Officer or
Chief Financial Officer of each of the Issuers, to the effect that: 
 (i) the representations and warranties of each of the
Issuers and the Guarantors contained in this Agreement are true and correct on and as of the Time of Execution and on and as of the Closing Date, and each of the Issuers and the Guarantors have performed all covenants and agreements and satisfied
all conditions on their part to be performed or satisfied hereunder at or prior to the Closing Date; 
 (ii) at the Closing
Date, since the date hereof or since the date of the most recent financial statements in the Pricing Disclosure Package and the Final Memorandum (exclusive of any amendment or supplement thereto after the date hereof), no event or development has
occurred, and no information has become known, that, individually or in the aggregate, has or would be reasonably likely to have a Material Adverse Effect; and 

(iii) the sale of the Notes hereunder has not been enjoined (temporarily or permanently). 

(h) On the Closing Date, the Initial Purchasers shall have received the Registration Rights Agreement executed by the Issuers
and the Guarantors and such agreement shall be in full force and effect. 
 On or before the Closing Date, the Initial Purchasers and
counsel for the Initial Purchasers shall have received such further documents, opinions, certificates, letters and schedules or instruments relating to the business, corporate, legal and financial affairs of the Issuers and the Guarantors as they
shall have heretofore reasonably requested from the Issuers. 

  
 22 

 All such documents, opinions, certificates, letters, schedules or instruments delivered
pursuant to this Agreement will comply with the provisions hereof only if they are reasonably satisfactory in all material respects to the Initial Purchasers and counsel for the Initial Purchasers. The Issuers shall furnish to the Initial Purchasers
such conformed copies of such documents, opinions, certificates, letters, schedules and instruments in such quantities as the Initial Purchasers shall reasonably request. 

Section 8. Offering of Notes; Restrictions on Transfer. 

(a) Each of the Initial Purchasers agrees with the Issuers (as to itself only) that (i) it has not and will not solicit offers for, or
offer or sell, the Notes by any form of general solicitation or general advertising (as those terms are used in Regulation D under the Act) or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Act; and
(ii) it has and will solicit offers for the Notes only from, and will offer the Notes only to (A) persons whom it reasonably believes to be “qualified institutional buyers” within the meaning of Rule 144A (each, a
“QIB”) in transactions meeting the requirements of Rule 144A or (B) to non-U.S. persons outside the United States (“non-U.S.
purchasers,” which term shall include dealers or other professional fiduciaries in the United States acting on a discretionary basis for non-U.S. beneficial owners (other than an estate or trust)) to
whom the Initial Purchasers reasonably believe may be made in reliance on Regulation S; provided, however, that, in the case of this clause (B), in purchasing such Notes such persons are deemed to have represented and agreed as
provided under the caption “Transfer Restrictions” contained in the Pricing Disclosure Package and the Final Memorandum. 
 (b)
Each of the Initial Purchasers represents and warrants (as to itself only) that (1) it is a QIB and (2) with respect to offers and sales outside the United States that (i) the Notes have not been and will not be offered or sold within
the United States or to, or for the account or benefit of, U.S. persons except in accordance with Regulation S under the Act or pursuant to an exemption from the registration requirements of the Act; and (ii) it has offered the Notes and will
offer and sell the Notes (A) as part of its distribution at any time and (B) otherwise until 40 days after the later of the commencement of the offering and the Closing Date, only in accordance with Rule 903 of Regulation S and,
accordingly, neither it nor any persons acting on its behalf have engaged or will engage in any directed selling efforts (within the meaning of Regulation S) with respect to the Notes, and any such persons have complied and will comply with the
offering restrictions requirement of Regulation S. 
 Terms used in this Section 8 and not defined in this Agreement have the meanings
given to them in Regulation S. 
 Section 9. Indemnification and Contribution. 

(a) The Issuers and the Guarantors, jointly and severally, agree to indemnify and hold harmless the Initial Purchasers, their directors,
officers, affiliates and each person, if any, who controls any Initial Purchaser within the meaning of Section 15 of the Act or Section 20 of the Exchange Act against any losses, claims, damages or liabilities to which any Initial
Purchaser, any such director, officer, affiliate or controlling person may become subject under the Act, the Exchange Act or otherwise, insofar as any such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are
based upon the following: 

  
 23 

 (i) any untrue statement or alleged untrue statement of any material fact
contained in the Pricing Disclosure Package, any Issuer Written Communication or Final Memorandum or any amendment or supplement thereto; or 

(ii) the omission or alleged omission to state, in the Pricing Disclosure Package, any Issuer Written Communication or the
Final Memorandum or any amendment or supplement thereto, a material fact necessary to make the statements therein not misleading; 
 and will reimburse, as
incurred, the Initial Purchasers, any such director, officer, affiliate and controlling person for any legal or other expenses reasonably incurred by the Initial Purchasers, their directors, officers, affiliates or controlling persons in connection
with investigating, defending against or appearing as a third-party witness in connection with any such loss, claim, damage, liability or action; provided, however, neither the Issuers nor the Guarantors will be liable in any such case
to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon any untrue statement or alleged untrue statement or omission or alleged omission made in the Pricing Disclosure Package or Final Memorandum or any
amendment or supplement thereto in reliance upon and in conformity with written information concerning such Initial Purchaser furnished to the Partnership by the Initial Purchasers through the Representative specifically for use therein. The
indemnity provided for in this Section 9 will be in addition to any liability that the Partnership may otherwise have to the indemnified parties. Neither the Issuers nor the Guarantors will be liable under this Section 9 for any settlement
of any claim or action effected without its prior written consent, which shall not be unreasonably withheld. 
 (b) Each Initial Purchaser,
severally and not jointly, agrees to indemnify and hold harmless each of the Issuers and Guarantors, and their respective directors, officers and each person, if any, who controls the Issuers or Guarantors within the meaning of Section 15 of
the Act or Section 20 of the Exchange Act against any losses, claims, damages or liabilities to which the Issuers or Guarantors or any such director, officer or controlling person may become subject under the Act, the Exchange Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in the Pricing Disclosure Package or Final
Memorandum or any amendment or supplement thereto, or (ii) the omission or the alleged omission to state therein a material fact necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that
such untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information concerning the Initial Purchasers, furnished to the Issuers and Guarantors by the Initial
Purchasers through the Representative specifically for use therein; and subject to the limitation set forth immediately preceding this clause, will reimburse, as incurred, any legal or other expenses reasonably incurred by the Issuers or Guarantors
or any such director, officer or controlling person in connection with investigating or defending against or appearing as a third party witness in connection with any such loss, claim, damage, liability or action in respect thereof. The indemnity
provided for in this Section 9 will be in addition to any liability that the Initial Purchasers may otherwise have to the indemnified parties. The Initial Purchasers shall not be liable under this Section 9 for any settlement of any claim
or action effected without their consent, which shall not be unreasonably withheld. 

  
 24 

 (c) Promptly after receipt by an indemnified party under this Section 9 of notice of
the commencement of any action for which such indemnified party is entitled to indemnification under this Section 9, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this
Section 9, notify the indemnifying party of the commencement thereof in writing; but the omission to so notify the indemnifying party (i) will not relieve it from any liability under paragraph (a) or (b) above unless and to the
extent such failure results in the forfeiture by the indemnifying party of substantial rights and defenses and (ii) will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the
indemnification obligation provided in paragraphs (a) and (b) above. In case any such action is brought against any indemnified party, and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be
entitled to participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party; provided,
however, that if (i) the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (ii) the defendants in any such action include both the indemnified
party and the indemnifying party and the indemnified party shall have been advised by counsel that there may be one or more legal defenses available to it and/or other indemnified parties that are different from or additional to those available to
the indemnifying party, or (iii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after receipt by the indemnifying party of
notice of the institution of such action, then, in each such case, the indemnifying party shall not have the right to direct the defense of such action on behalf of such indemnified party or parties and such indemnified party or parties shall have
the right to select separate counsel to defend such action on behalf of such indemnified party or parties. After notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof and approval by such
indemnified party of counsel appointed to defend such action, the indemnifying party will not be liable to such indemnified party under this Section 9 for any legal or other expenses, other than reasonable costs of investigation, subsequently
incurred by such indemnified party in connection with the defense thereof, unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the immediately preceding sentence (it being understood, however,
that in connection with such action the indemnifying party shall not be liable for the expenses of more than one separate counsel (in addition to local counsel) in any one action or separate but substantially similar actions in the same jurisdiction
arising out of the same general allegations or circumstances, designated by the Initial Purchasers in the case of paragraph (a) of this Section 9 or the Issuers and Guarantors in the case of paragraph (b) of this Section 9,
representing the indemnified parties under such paragraph (a) or paragraph (b), as the case may be, who are parties to such action or actions) or (ii) the indemnifying party has authorized in writing the employment of counsel for the
indemnified party at the expense of the indemnifying party. All fees and expenses reimbursed pursuant to this paragraph (c) shall be reimbursed as they are incurred. After such notice from the indemnifying party to such indemnified party, the
indemnifying party will not be liable for the costs and expenses of any settlement of such action effected by such indemnified party without the prior written consent of the indemnifying party (which consent shall not be unreasonably withheld),
unless such indemnifying party waived in 

  
 25 

 
writing its rights under this Section 9, in which case the indemnified party may effect such a settlement without such consent. No indemnifying party shall, without the prior written consent
of the indemnified party, effect any settlement or compromise of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party, or indemnity could have been sought hereunder by any indemnified party,
unless such settlement (A) includes an unconditional written release of the indemnified party, in form and substance reasonably satisfactory to the indemnified party, from all liability on claims that are the subject matter of such proceeding
and (B) does not include any statement as to an admission of fault, culpability or failure to act by or on behalf of any indemnified party. 

(d) In circumstances in which the indemnity agreement provided for in the preceding paragraphs of this Section 9 is unavailable to, or
insufficient to hold harmless, an indemnified party in respect of any losses, claims, damages or liabilities (or actions in respect thereof), each indemnifying party, in order to provide for just and equitable contribution, shall contribute to the
amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect (i) the relative benefits received by the indemnifying
party or parties on the one hand and the indemnified party on the other from the offering of the Notes or if the allocation provided by the foregoing clause (i) is not permitted by applicable law, not only such relative benefits but also the
relative fault of the indemnifying party or parties on the one hand and the indemnified party on the other in connection with the statements or omissions or alleged statements or omissions that resulted in such losses, claims, damages or liabilities
(or actions in respect thereof). The relative benefits received by the Issuers and Guarantors on the one hand and the Initial Purchasers on the other shall be deemed to be in the same proportion as the total proceeds from the offering (after
deducting discounts and commissions but before deducting expenses) received by the Issuers and Guarantors bear to the total discounts and commissions received by such Initial Purchaser. The relative fault of the parties shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Issuers and Guarantors on the one hand, or such
Initial Purchaser on the other, the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission or alleged statement or omission, and any other equitable considerations appropriate
in the circumstances. The Issuers, the Guarantors and the Initial Purchasers agree that it would not be equitable if the amount of such contribution were determined by pro rata or per capita allocation or by any other method of allocation that does
not take into account the equitable considerations referred to in the first sentence of this paragraph (d). Notwithstanding any other provision of this paragraph (d), no Initial Purchaser shall be obligated to make contributions hereunder
that in the aggregate exceed the total discounts, commissions and other compensation received by such Initial Purchaser under this Agreement, less the aggregate amount of any damages that such Initial Purchaser has otherwise been required to pay by
reason of the untrue or alleged untrue statements or the omissions or alleged omissions to state a material fact, and no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The obligations of the Initial Purchasers are several and not joint. For purposes of this paragraph (d), each director, officer and affiliate of the Initial
Purchasers and each person, if any, who controls any Initial Purchaser within the meaning of Section 15 of the Act or Section 20 of the Exchange Act shall have the same rights to 

  
 26 

 
contribution as the Initial Purchasers, and each director of either of the Issuers or any of the Guarantors, each officer of either of the Issuers or any of the Guarantors and each person, if
any, who controls either of the Issuers or any of the Guarantors within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, shall have the same rights to contribution as the Partnership. 

Section 10. Survival Clause. The respective representations, warranties, agreements, covenants, indemnities and other statements
of each of the Issuers, Guarantors, their respective officers and the Initial Purchasers set forth in this Agreement or made by or on behalf of them pursuant to this Agreement shall remain in full force and effect, regardless of (i) any
investigation made by or on behalf of any of the Issuers, Guarantors, any of their respective officers or directors, the Initial Purchasers, any of their officers, directors, affiliates or controlling persons referred to in Section 9 hereof and
(ii) delivery of and payment for the Notes. The respective agreements, covenants, indemnities and other statements set forth in Sections 6, 9, 10 and 15 hereof shall remain in full force and effect, regardless of any termination or
cancellation of this Agreement. 
 Section 11. Termination. 

(a) This Agreement may be terminated in the sole discretion of the Initial Purchasers by notice to the Issuers given prior to the Closing Date
in the event that the Issuers shall have failed, refused or been unable to perform all obligations and satisfy all conditions on its part to be performed or satisfied hereunder at or prior thereto or, if, after the date hereof and at or prior to the
Closing Date, 
 (i) trading in securities of the Partnership or Targa Resources Corp. shall have been suspended by the
Commission or the New York Stock Exchange; 
 (ii) there shall have been, in the sole judgment of the Representative, any
event or development that, individually or in the aggregate, has or could be reasonably likely to have a Material Adverse Effect (including without limitation a change in control of the Issuers or the Guarantors), except in each case as described in
the Pricing Disclosure Package and the Final Memorandum (exclusive of any amendment or supplement thereto); 
 (iii) trading
in securities generally on the New York Stock Exchange shall have been suspended or materially limited or minimum or maximum prices shall have been established on any such exchange or market; 

(iv) a banking moratorium shall have been declared by New York or United States authorities or a material disruption in
commercial banking or securities settlement or clearance services in the United States shall have occurred; 
 (v) there
shall have been (A) an outbreak or escalation of hostilities between the United States and any foreign power or (B) an outbreak or escalation of any other insurrection or armed conflict involving the United States or any other national or
international calamity or emergency, which in the case of (A) 

  
 27 

 
and (B) above and in the sole judgment of the Representative, makes it impracticable or inadvisable to proceed with the offering or the delivery of the Notes as contemplated by the Pricing
Disclosure Package and the Final Memorandum; or 
 (vi) any securities of the Partnership shall have been downgraded by any
nationally recognized statistical rating organization or any such organization shall have publicly announced that it has under surveillance or review, or has changed its outlook with respect to, its ratings of any securities of the Partnership
(other than an announcement with positive implications of a possible upgrading). 
 (b) Termination of this Agreement pursuant to this
Section 11 shall be without liability of any party to any other party except as provided in Section 10 hereof. 
 Section 12.
Default of One or More of the Several Initial Purchasers. 
 (a) If any one or more of the several Initial Purchasers shall fail or
refuse to purchase the Notes that it or they have agreed to purchase hereunder on the Closing Date, and the aggregate number of the Notes which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase does not
exceed 10% of the aggregate number of the Notes to be purchased on such date, the other Initial Purchasers shall be obligated, severally, in the proportions that the number of Notes set forth opposite their respective names
on Schedule 1 bears to the aggregate number of the Notes set forth opposite the names of all such non-defaulting Initial Purchasers, or in such other proportions as may be specified by the
Initial Purchasers with the consent of the non-defaulting Initial Purchasers, to purchase the Notes which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase on the
Closing Date. If any one or more of the Initial Purchasers shall fail or refuse to purchase the Notes and the aggregate number of the Notes with respect to which such default occurs exceeds 10% of the aggregate number of the Notes to be purchased on
the Closing Date, and arrangements satisfactory to the Initial Purchasers and the Issuers for the purchase of such Notes are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other
party except that the provisions of Sections 6 and 9 hereof shall at all times be effective and shall survive such termination. In any such case either the Initial Purchasers or the Issuers shall have the right to postpone the Closing Date, as
the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Final Offering Memorandum or any other documents or arrangements may be effected. 

(b) As used in this Agreement, the term “Initial Purchaser” shall be deemed to include any person substituted for a
defaulting Initial Purchaser under this Section 12. Any action taken under this Section 12 shall not relieve any defaulting Initial Purchaser from liability in respect of any default of such Initial Purchaser under this Agreement. 

Section 13. Information Supplied by the Initial Purchasers. The statements set forth in the fourth paragraph and the tenth through
twelfth paragraphs under the heading “Plan of Distribution” in the Preliminary Memorandum and the Final Memorandum (to the extent such statements relate to the Initial Purchaser) constitute the only information furnished by the Initial
Purchasers to the Issuers for the purposes of Sections 2(a) and 9 hereof. 

  
 28 

 Section 14. Notices. All communications hereunder shall be in writing and, if
sent to the Initial Purchasers, shall be mailed or delivered to Wells Fargo Securities, LLC at 550 South Tryon Street, 5th Floor, Charlotte, NC 28202, Attention: Transaction Management; and if
sent to the Partnership, shall be mailed or delivered to the Partnership at 811 Louisiana Street, Suite 2100, Houston, Texas 77002, Attention: Chief Financial Officer; with a copy to Vinson & Elkins L.L.P., 1001 Fannin Street, Suite 2500,
Houston, Texas 77002, Attention: Thomas G. Zentner. 
 All such notices and communications shall be deemed to have been duly given: when
delivered by hand, if personally delivered; five business days after being deposited in the mail, postage prepaid, if mailed; and one business day after being timely delivered to a next-day air courier. 

Section 15. Successors. This Agreement shall inure to the benefit of and be binding upon the Initial Purchasers, the Issuers and
their respective successors and legal representatives, and nothing expressed or mentioned in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this
Agreement, or any provisions herein contained; this Agreement and all conditions and provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person except that (i) the
indemnities of the Issuers contained in Section 9 of this Agreement shall also be for the benefit of the directors, officers and employees of the Initial Purchasers and any person or persons who control the Initial Purchasers within the meaning
of Section 15 of the Act or Section 20 of the Exchange Act and (ii) the indemnities of the Initial Purchasers contained in Section 9 of this Agreement shall also be for the benefit of the directors of the Issuers, their officers
and any person or persons who control the Issuers within the meaning of Section 15 of the Act or Section 20 of the Exchange Act. No purchaser of Notes from the Initial Purchasers will be deemed a successor because of such purchase. 

Section 16. APPLICABLE LAW. THE VALIDITY AND INTERPRETATION OF THIS AGREEMENT, ANY CLAIM, COUNTERCLAIM OR DISPUTE OF ANY KIND OR
NATURE WHATSOEVER ARISING OUT OF OR IN ANY WAY RELATING TO THIS AGREEMENT, DIRECTLY OR INDIRECTLY, AND THE TERMS AND CONDITIONS SET FORTH HEREIN SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO
CONTRACTS MADE AND TO BE PERFORMED WHOLLY THEREIN, WITHOUT GIVING EFFECT TO ANY PROVISIONS THEREOF RELATING TO CONFLICTS OF LAW. 

Section 17. No Advisory or Fiduciary Responsibility. The Issuers and the Guarantors acknowledge and agree that (i) the
purchase and sale of the Notes pursuant to this Agreement is an arm’s-length commercial transaction between the Issuers, on the one hand, and the Initial Purchasers, on the other, (ii) in connection
therewith and with the process leading to such transaction each Initial Purchaser is acting solely as a principal and not the agent or fiduciary of either of the Issuers, (iii) no Initial Purchaser has assumed an advisory or fiduciary
responsibility in favor of either of the Issuers with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Initial Purchaser has advised or is 

  
 29 

 
currently advising either of the Issuers on other matters) or any other obligation to the Issuers except the obligations expressly set forth in this Agreement and (iv) each of the Issuers
has consulted its own legal and financial advisors to the extent it deemed appropriate. Each of the Issuers agrees that it will not claim that any Initial Purchaser has rendered advisory services of any nature or respect, or owes a fiduciary or
similar duty to either of the Issuers, in connection with such transaction or the process leading thereto. 
 Section 18. USA
PATRIOT Act. In accordance with the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Initial Purchasers are required to obtain, verify and
record information that identifies their respective clients, including the Issuers, which information may include the name and address of their respective clients, as well as other information that will allow the Initial Purchasers to properly
identify their respective clients. 
 Section 19. Recognition of the U.S. Special Resolution Regimes. 

(a) In the event that any Initial Purchaser that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Initial Purchaser of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. 
 (b) In
the event that any Initial Purchaser that is a Covered Entity or a BHC Act Affiliate of such Initial Purchaser becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against
such Initial Purchaser are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United
States. 
 For purposes of this Section 19: (a) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and
shall be interpreted in accordance with, 12 U.S.C. § 1841(k); (b) “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R.
§ 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12
C.F.R. § 382.2(b); (c) “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (d) “U.S. Special
Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated
thereunder. 
 Section 20. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. 

  
 30 

 If the foregoing correctly sets forth our understanding, please indicate your acceptance
thereof in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Issuers and the Initial Purchasers. 

 

					
	Very truly yours,
	
	TARGA RESOURCES PARTNERS LP
		
	By:	 	Targa Resources GP LLC,
		 	Its general partner
		
	By:	 	 /s/ Jennifer R. Kneale

		 	Name:	 	Jennifer R. Kneale
		 	Title:	 	Chief Financial Officer

  

					
	TARGA RESOURCES PARTNERS FINANCE CORPORATION
		
	By:	 	 /s/ Jennifer R. Kneale

		 	Name:	 	Jennifer R. Kneale
		 	Title:	 	Chief Financial Officer

  
 Signature Page to
the Purchase Agreement 

 
					
	FCPP PIPELINE, LLC
	FLAG CITY PROCESSING PARTNERS, LLC
	SLIDER WESTOK GATHERING, LLC
	TARGA CAPITAL LLC
	TARGA CHANEY DELL LLC
	TARGA CHANNELVIEW LLC
	TARGA COGEN LLC
	TARGA DELAWARE LLC
	TARGA DOWNSTREAM LLC
	TARGA GAS MARKETING LLC
	TARGA GAS PIPELINE LLC
	TARGA GAS PROCESSING LLC
	TARGA INTRASTATE PIPELINE LLC
	TARGA LIQUIDS MARKETING AND TRADE LLC
	TARGA LOUISIANA INTRASTATE LLC
	TARGA MIDKIFF LLC
	TARGA MIDLAND CRUDE LLC
	TARGA MIDLAND LLC
	TARGA MIDSTREAM SERVICES LLC
	TARGA MLP CAPITAL LLC
	TARGA NGL PIPELINE COMPANY LLC
	TARGA PIPELINE MID-CONTINENT HOLDINGS LLC
	TARGA PIPELINE MID-CONTINENT LLC
	TARGA PIPELINE PARTNERS GP LLC
	TARGA RESOURCES OPERATING GP LLC
	TARGA RESOURCES OPERATING LLC
	TARGA SOUTHERN DELAWARE LLC
	TARGA SOUTHOK NGL PIPELINE LLC
	TARGA TRAIN 8 LLC
	TARGA TRANSPORT LLC
	TPL ARKOMA HOLDINGS LLC
	TPL ARKOMA INC.
	TPL ARKOMA MIDSTREAM LLC
	TPL GAS TREATING LLC
	TPL SOUTHTEX MIDSTREAM LLC
	TPL SOUTHTEX PIPELINE COMPANY LLC
	 VELMA INTRASTATE GAS TRANSMISSION COMPANY, LLC

	VERSADO GAS PROCESSORS, L.L.C.
		
	By:	 	 /s/ Jennifer R. Kneale

		 	Name:	 	Jennifer R. Kneale
		 	Title:	 	Chief Financial Officer

  
 Signature Page to
the Purchase Agreement 

 
							
	TARGA PIPELINE OPERATING PARTNERSHIP LP
	TARGA PIPELINE PARTNERS LP
		
	By:	 	Targa Pipeline Partners GP LLC, its general partner
			
		 	By:	 	 /s/ Jennifer R. Kneale

		 		 	Name:	 	Jennifer R. Kneale
		 		 	Title:	 	Chief Financial Officer

  

							
	TPL BARNETT LLC
		
	By:	 	Targa Pipeline Mid-Continent Holdings LLC, its sole member
			
		 	By:	 	 /s/ Jennifer R. Kneale

		 		 	Name:	 	Jennifer R. Kneale
		 		 	Title:	 	Chief Financial Officer

  

							
	PECOS PIPELINE LLC
	TESUQUE PIPELINE, LLC
		
	By:	 	TPL Barnett LLC, its sole member
		
	By:	 	Targa Pipeline Mid-Continent Holdings LLC, its sole member
			
		 	By:	 	 /s/ Jennifer R. Kneale

		 		 	Name:	 	Jennifer R. Kneale
		 		 	Title:	 	Chief Financial Officer

  
 Signature Page to
the Purchase Agreement 

 
							
	VELMA GAS PROCESSING COMPANY, LLC
		
	By:	 	Targa Pipeline Mid-Continent LLC, its sole member
			
		 	By:	 	 /s/ Jennifer R. Kneale

		 		 	Name:	 	Jennifer R. Kneale
		 		 	Title:	 	Chief Financial Officer

  

							
	 TARGA SOUTHTEX MIDSTREAM COMPANY LP

	 TPL SOUTHTEX GAS UTILITY COMPANY LP

	 TPL SOUTHTEX MIDSTREAM HOLDING COMPANY LP

	 TPL SOUTHTEX PROCESSING COMPANY LP

	 TPL SOUTHTEX TRANSMISSION COMPANY LP

		
	By:	 	TPL SouthTex Pipeline Company LLC, its general partner
			
		 	By:	 	 /s/ Jennifer R. Kneale

		 		 	Name:	 	Jennifer R. Kneale
		 		 	Title:	 	Chief Financial Officer

  
 Signature Page to
the Purchase Agreement 

							
	The foregoing Agreement is hereby confirmed and accepted as of the date first above written.
	
	WELLS FARGO SECURITIES, LLC
	
	Acting on behalf of itself and as the Representative of the several Initial Purchasers
		
	By:	 	Wells Fargo Securities, LLC
			
		 	By:	 	 /s/ Todd Schanzlin

		 		 	Name:	 	Todd Schanzlin
		 		 	Title:	 	Managing Director

  
 Signature Page to
the Purchase Agreement 

 SCHEDULE 1 
  

					
	 Initial Purchasers
	  	Principal Amount of the Notes	 
		
	 Wells Fargo Securities, LLC
	  	$	200,000,000	 
	 BofA Securities, Inc.
	  	 	90,000,000	 
	 Capital One Securities, Inc.
	  	 	90,000,000	 
	 Citigroup Global Markets Inc.
	  	 	90,000,000	 
	 Goldman Sachs & Co. LLC
	  	 	90,000,000	 
	 RBC Capital Markets, LLC
	  	 	90,000,000	 
	 ING Financial Markets LLC
	  	 	40,000,000	 
	 J.P. Morgan Securities LLC
	  	 	40,000,000	 
	 Morgan Stanley & Co. LLC
	  	 	40,000,000	 
	 Scotia Capital (USA) Inc.
	  	 	40,000,000	 
	 SMBC Nikko Securities America, Inc.
	  	 	40,000,000	 
	 TD Securities (USA) LLC
	  	 	40,000,000	 
	 Truist Securities, Inc.
	  	 	40,000,000	 
	 Raymond James & Associates, Inc.
	  	 	20,000,000	 
	 BMO Capital Markets Corp.
	  	 	15,000,000	 
	 CIBC World Markets Corp.
	  	 	15,000,000	 
	 Huntington Securities, Inc.
	  	 	10,000,000	 
	 U.S. Bancorp Investments, Inc.
	  	 	10,000,000	 
		  	  
	  
	 
	 Total
	  	$	1,000,000,000	 
		  	  
	  
	 

  
 Schedule 1-1 

 SCHEDULE 2 

Jurisdiction of Formation for the Partnership and General Partner 

 

			
	 Name
	  	 Jurisdiction of Organization

		
	Targa Resources Partners LP	  	Delaware
	Targa Resources GP LLC	  	Delaware

 Subsidiaries of the Partnership 

 

			
	 Name
	  	 Jurisdiction of Organization

	Cedar Bayou Fractionators, L.P.	  	Delaware
	Centrahoma Processing LLC	  	Delaware
	DEVCO Holdings LLC	  	Delaware
	Downstream Energy Ventures Co., L.L.C.	  	Delaware
	FCPP Pipeline, LLC	  	Delaware
	Flag City Processing Partners, LLC	  	Delaware
	Floridian Natural Gas Storage Company, LLC	  	Delaware
	Grand Prix Pipeline LLC	  	Delaware
	Pecos Pipeline LLC	  	Delaware
	Sajet Development LLC	  	Delaware
	Sajet Properties LLC	  	Delaware
	Sajet Resources LLC	  	Delaware
	Salta Properties LLC	  	Delaware
	Setting Sun Pipeline Corporation	  	Delaware
	Slider WestOk Gathering, LLC	  	Delaware
	T2 LaSalle Gas Utility LLC	  	Texas
	T2 LaSalle Gathering Company LLC	  	Delaware
	Targa Badlands Holdings LLC	  	Delaware
	Targa Badlands LLC	  	Delaware
	Targa Canada Liquids Inc.	  	British Columbia, Canada
	Targa Capital LLC	  	Delaware
	Targa Chaney Dell LLC	  	Delaware
	Targa Channelview LLC	  	Delaware
	Targa Cogen LLC	  	Delaware
	Targa Delaware LLC	  	Delaware
	Targa Downstream LLC	  	Delaware
	Targa Gas Marketing LLC	  	Delaware
	Targa Gas Pipeline LLC	  	Delaware
	Targa Gas Processing LLC	  	Delaware
	Targa Holding LLC	  	Delaware
	Targa Intrastate Pipeline LLC	  	Delaware
	Targa Liquids Marketing and Trade LLC	  	Delaware
	Targa Louisiana Intrastate LLC	  	Delaware
	Targa Midkiff LLC	  	Delaware
	Targa Midland Gas Pipeline LLC	  	Delaware

  
 Schedule 2-1 

			
	Targa Midland Crude LLC	  	Delaware
	Targa Midland LLC	  	Delaware
	Targa Midstream Services LLC	  	Delaware
	Targa MLP Capital LLC	  	Delaware
	Targa NGL Pipeline Company LLC	  	Delaware
	Targa Pipeline Escrow LLC	  	Delaware
	Targa Pipeline Finance Corporation	  	Delaware
	Targa Pipeline Mid-Continent Holdings LLC	  	Delaware
	Targa Pipeline Mid-Continent LLC	  	Delaware
	Targa Pipeline Mid-Continent WestOk LLC	  	Delaware
	Targa Pipeline Mid-Continent WestTex LLC	  	Delaware
	Targa Pipeline Operating Partnership LP	  	Delaware
	Targa Pipeline Partners GP LLC	  	Delaware
	Targa Pipeline Partners LP	  	Delaware
	Targa Receivables LLC	  	Delaware
	Targa Resources Operating GP LLC	  	Delaware
	Targa Resources Operating LLC	  	Delaware
	Targa Resources Partners Finance Corporation	  	Delaware
	Targa Southern Delaware LLC	  	Delaware
	Targa SouthOk NGL Pipeline LLC	  	Oklahoma
	Targa SouthTex Midstream Company LP	  	Texas
	Targa Train 6 LLC	  	Delaware
	Targa Train 7 LLC	  	Delaware
	Targa Train 8 LLC	  	Delaware
	Targa Transport LLC	  	Delaware
	Terracotta Ventures LLC	  	Delaware
	Tesla Resources LLC	  	Delaware
	Tesuque Pipeline, LLC	  	Delaware
	TPL Arkoma Holdings LLC	  	Delaware
	TPL Arkoma Inc.	  	Delaware
	TPL Arkoma Midstream LLC	  	Delaware
	TPL Barnett LLC	  	Delaware
	TPL Gas Treating LLC	  	Delaware
	TPL SouthTex Gas Utility Company LP	  	Texas
	TPL SouthTex Midstream Holding Company LP	  	Texas
	TPL SouthTex Midstream LLC	  	Delaware
	TPL SouthTex Pipeline Company LLC	  	Texas
	TPL SouthTex Processing Company LP	  	Texas
	TPL SouthTex Transmission Company LP	  	Texas
	Velma Gas Processing Company, LLC	  	Delaware
	Velma Intrastate Gas Transmission Company, LLC	  	Delaware
	Venice Energy Services Company, L.L.C.	  	Delaware
	Versado Gas Processors, L.L.C.	  	Delaware

  
 Schedule 2-2 

 SCHEDULE 3 

Non-Guarantor Subsidiaries 

 

			
	 Name
	  	 Jurisdiction of Organization

		
	Cedar Bayou Fractionators, L.P.	  	Delaware
	Centrahoma Processing, LLC	  	Delaware
	DEVCO Holdings LLC	  	Delaware
	Downstream Energy Ventures Co., L.L.C.	  	Delaware
	Floridian Natural Gas Storage Company, LLC	  	Delaware
	Grand Prix Pipeline LLC	  	Delaware
	Sajet Development LLC	  	Delaware
	Sajet Properties LLC	  	Delaware
	Sajet Resources LLC	  	Delaware
	Salta Properties LLC	  	Delaware
	Setting Sun Pipeline Corporation	  	Delaware
	T2 LaSalle Gas Utility LLC	  	Texas
	T2 LaSalle Gathering Company LLC	  	Delaware
	Targa Badlands Holdings LLC	  	Delaware
	Targa Badlands LLC	  	Delaware
	Targa Canada Liquids Inc.	  	British Columbia, Canada
	Targa Holding LLC	  	Delaware
	Targa Midland Gas Pipeline LLC	  	Delaware
	Targa Pipeline Escrow LLC	  	Delaware
	Targa Pipeline Finance Corporation	  	Delaware
	Targa Pipeline Mid-Continent WestOk LLC	  	Delaware
	Targa Pipeline Mid-Continent WestTex LLC	  	Delaware
	Targa Receivables LLC	  	Delaware
	Targa Resources Partners Finance Corporation	  	Delaware
	Targa Train 6 LLC	  	Delaware
	Targa Train 7 LLC	  	Delaware
	Terracotta Ventures LLC	  	Delaware
	Tesla Resources LLC	  	Delaware
	Venice Energy Services Company, L.L.C.	  	Delaware

  
 Schedule 3-1 

 SCHEDULE 4 

Guarantors 
  

			
	 Name
	  	 Jurisdiction of Organization

		
	FCPP Pipeline, LLC	  	Delaware
	Flag City Processing Partners, LLC	  	Delaware
	Pecos Pipeline LLC	  	Delaware
	Slider WestOk Gathering, LLC	  	Delaware
	Targa Capital LLC	  	Delaware
	Targa Chaney Dell LLC	  	Delaware
	Targa Channelview LLC	  	Delaware
	Targa Cogen LLC	  	Delaware
	Targa Delaware LLC	  	Delaware
	Targa Downstream LLC	  	Delaware
	Targa Gas Marketing LLC	  	Delaware
	Targa Gas Pipeline LLC	  	Delaware
	Targa Gas Processing LLC	  	Delaware
	Targa Intrastate Pipeline LLC	  	Delaware
	Targa Liquids Marketing and Trade LLC	  	Delaware
	Targa Louisiana Intrastate LLC	  	Delaware
	Targa Midkiff LLC	  	Delaware
	Targa Midland Crude LLC	  	Delaware
	Targa Midland LLC	  	Delaware
	Targa Midstream Services LLC	  	Delaware
	Targa MLP Capital LLC	  	Delaware
	Targa NGL Pipeline Company LLC	  	Delaware
	Targa Pipeline Mid-Continent Holdings LLC	  	Delaware
	Targa Pipeline Mid-Continent LLC	  	Delaware
	Targa Pipeline Operating Partnership LP	  	Delaware
	Targa Pipeline Partners GP LLC	  	Delaware
	Targa Pipeline Partners LP	  	Delaware
	Targa Resources Operating GP LLC	  	Delaware
	Targa Resources Operating LLC	  	Delaware
	Targa Southern Delaware LLC	  	Delaware
	Targa SouthOk NGL Pipeline LLC	  	Oklahoma
	Targa SouthTex Midstream Company LP	  	Texas
	Targa Train 8 LLC	  	Delaware
	Targa Transport LLC	  	Delaware
	Tesuque Pipeline, LLC	  	Delaware
	TPL Arkoma Holdings LLC	  	Delaware
	TPL Arkoma Inc.	  	Delaware
	TPL Arkoma Midstream LLC	  	Delaware
	TPL Barnett LLC	  	Delaware
	TPL Gas Treating LLC	  	Delaware

  
 Schedule 4-1 

			
	TPL SouthTex Gas Utility Company LP	  	Texas
	TPL SouthTex Midstream Holding Company LP	  	Texas
	TPL SouthTex Midstream LLC	  	Delaware
	TPL SouthTex Pipeline Company LLC	  	Texas
	TPL SouthTex Processing Company LP	  	Texas
	TPL SouthTex Transmission Company LP	  	Texas
	Velma Gas Processing Company, LLC	  	Delaware
	Velma Intrastate Gas Transmission Company, LLC	  	Delaware
	Versado Gas Processors, L.L.C.	  	Delaware

  
 Schedule 4-2 

 SCHEDULE 5 

Material Subsidiaries 

(Certain entities are also listed on Schedule 4) 
  

			
	 Name
	  	 Jurisdiction of Organization

	Centrahoma Processing LLC	  	Delaware
	Targa Downstream LLC	  	Delaware
	Targa Pipeline Mid-Continent LLC	  	Delaware
	Targa Pipeline Mid-Continent WestOk LLC	  	Delaware
	Targa Pipeline Mid-Continent WestTex LLC	  	Delaware
	Grand Prix Pipeline LLC	  	Delaware

  
 Schedule 5-1 

 SCHEDULE 6 

Excluded Guarantors 
  

			
	 Name
	  	 Jurisdiction of Organization

	FCPP Pipeline, LLC	  	Delaware
	Flag City Processing Partners, LLC	  	Delaware
	Pecos Pipeline LLC	  	Delaware
	Slider WestOk Gathering, LLC	  	Delaware
	Targa Badlands Holdings LLC	  	Delaware
	Targa Chaney Dell LLC	  	Delaware
	Targa Channelview LLC	  	Delaware
	Targa Delaware LLC	  	Delaware
	Targa Midkiff LLC	  	Delaware
	Targa Midland LLC	  	Delaware
	Targa Pipeline Mid-Continent Holdings LLC	  	Delaware
	Targa Pipeline Mid-Continent LLC	  	Delaware
	Targa Pipeline Operating Partnership LP	  	Delaware
	Targa Pipeline Partners GP LLC	  	Delaware
	Targa Pipeline Partners LP	  	Delaware
	Targa Southern Delaware LLC	  	Delaware
	Targa SouthOk NGL Pipeline LLC	  	Oklahoma
	Targa SouthTex Midstream Company LP	  	Texas
	Terracotta Ventures LLC	  	Delaware
	Tesuque Pipeline, LLC	  	Delaware
	TPL Arkoma Holdings LLC	  	Delaware
	TPL Arkoma Inc.	  	Delaware
	TPL Arkoma Midstream LLC	  	Delaware
	TPL Barnett LLC	  	Delaware
	TPL Gas Treating LLC	  	Delaware
	TPL SouthTex Gas Utility Company LP	  	Texas
	TPL SouthTex Midstream Holding Company LP	  	Texas
	TPL SouthTex Midstream LLC	  	Delaware
	TPL SouthTex Pipeline Company LLC	  	Texas
	TPL SouthTex Processing Company LP	  	Texas
	TPL SouthTex Transmission Company LP	  	Texas
	Velma Gas Processing Company, LLC	  	Delaware
	Velma Intrastate Gas Transmission Company, LLC	  	Delaware
	Versado Gas Processors, L.L.C.	  	Delaware

  
 Schedule 6-1 

 ANNEX A 

US $1,000,000,000 
  

 
 TARGA RESOURCES PARTNERS LP 

TARGA RESOURCES PARTNERS FINANCE CORPORATION 

4.875% Senior Notes due 2031 

August 11, 2020 
  

 
 This Pricing Supplement is qualified in its entirety
by reference to the Preliminary Offering Memorandum dated August 11, 2020. The information in this Pricing Supplement supplements the Preliminary Offering Memorandum and supersedes the information in the Preliminary Offering Memorandum to the
extent inconsistent with the information in the Preliminary Offering Memorandum. Capitalized terms used but not defined in this Pricing Supplement have the respective meanings ascribed to them in the Preliminary Offering Memorandum. 

The notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and are being offered only to
qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons in accordance with Regulation S under the Securities Act. The notes are not
transferable except in accordance with the restrictions described under “Transfer Restrictions” in the Preliminary Offering Memorandum. 

Terms Applicable to the 4.875% Senior Notes due 2031 
  

					
		
	Issuers:	 	 Targa Resources Partners LP
 Targa
Resources Partners Finance Corporation

		
	Principal Amount:	 	$1,000,000,000
		
	Title of Securities:	 	4.875% Senior Notes due 2031 (the “Notes”)
		
	Final Maturity Date:	 	February 1, 2031
		
	Issue Price:	 	100%, plus accrued interest, if any, from August 18, 2020
		
	Coupon:	 	4.875%
		
	Yield to Maturity:	 	4.875%
		
	Spread to Benchmark Treasury:	 	+422 basis points
		
	Benchmark Treasury:	 	0.625% due May 15, 2030
		
	Benchmark Treasury Yield:	 	0.651%
		
	Interest Payment Dates:	 	February 1 and August 1, beginning on February 1, 2021
		
	Record Dates:	 	January 15 and July 15

  
 Annex A-1 

					
		
	Make-Whole Redemption	 	Make-whole redemption at T+50 basis points prior to February 1, 2026
		
	Optional Redemption:	 	In addition, on or after February 1, 2026, the Issuers may redeem all or a part of the Notes at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest
and Liquidated Damages, if any, on the Notes redeemed, to the applicable redemption date, if redeemed during the twelve-month period beginning on February 1 of each year indicated below:
	 	 	 Year
	  	 Price

		 	2026	  	102.438%
		 	2027	  	101.625%
		 	2028	  	100.813%
		 	2029 and thereafter	  	100.000%
		
	Optional Redemption After Certain Equity Offerings:	 	Up to 35% at 104.875% prior to February 1, 2024
		
	 Initial Purchasers:
	 	Wells Fargo Securities, LLC
		 	BofA Securities, Inc.
		 	Capital One Securities, Inc.
		 	Citigroup Global Markets, Inc.
		 	Goldman Sachs & Co. LLC
		 	RBC Capital Markets, LLC
		 	ING Financial Markets LLC
		 	J.P. Morgan Securities LLC
		 	Morgan Stanley & Co. LLC
		 	Scotia Capital (USA) Inc.
		 	SMBC Nikko Securities America, Inc.
		 	TD Securities (USA) LLC
		 	Truist Securities, Inc.
		 	Raymond James & Associates, Inc.
		 	BMO Capital Markets Corp.
		 	CIBC World Markets Corp.
		 	Huntington Securities, Inc.
		 	U.S. Bancorp Investments, Inc.
		
	Trade Date:	 	August 11, 2020
		
	Settlement Date:	 	August 18, 2020 (T+5 business days)
		
	Denominations:	 	$2,000 and integral multiples of $1,000 in excess thereof
		
	Distribution:	 	144A and Regulation S with registration rights as set forth in the Preliminary Offering Memorandum
			
	CUSIP and ISIN Numbers:	 	144A Notes:	  	Reg S Notes:
		 	CUSIP: 87612BBR2	  	CUSIP: U87571AS1
		 	ISIN: US87612BBR24	  	ISIN: USU87571AS15

 Updates to Preliminary Offering Memorandum: 

The following disclosure in each location where such information appears in the Preliminary Offering Memorandum is amended to read as follows: 

“As of June 30, 2020, and after giving effect to this offering and the use of proceeds therefrom, we would have had
$7,418.5 million in total indebtedness, with $39.9 million in 

  
 Annex A-2 

 
borrowings outstanding and $2,103.3 million of borrowing capacity under our senior secured revolving credit facility and $250.0 million of borrowings and no borrowing capacity under our
Securitization Facility.” 
 Other information (including financial information) presented in the Preliminary Offering Memorandum is deemed to have
changed to the extent effected by the changes described herein. 
 This material is confidential and is for your information only and is not intended
to be used by anyone other than you. This information does not purport to be a complete description of these notes or the offering. Please refer to the Preliminary Offering Memorandum for a complete description. 

Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices
were automatically generated as a result of this communication being sent via Bloomberg email or another communication system. 

  
 Annex A-3 

 ANNEX B 
  

	1.	 Fourth Amended and Restated Credit Agreement, dated June 29, 2018, by and among the Targa Resources
Partners LP, Bank of America, N.A., as Administrative Agent, Collateral Agent and Swing Line Lender, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Barclays Bank PLC, Capital One, National Association, Citigroup Global Markets Inc.,
RBC Capital Markets, LLC and Wells Fargo Bank, National Association, as Co-Syndication Agents, BBVA Compass, Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., PNC Bank, National
Association, and The Toronto-Dominion Bank, New York Branch, as Co-Documentation Agents and the other lenders and L/C Issuers party thereto, as amended 

 

	2.	 Indenture dated as of October 25, 2012, among Targa Resources Partners LP, Targa Resources Partners
Finance Corporation, the Guarantors named therein and U.S. Bank National Association, as supplemented 

  

	3.	 Indenture dated as of May 14, 2013, among Targa Resources Partners LP, Targa Resources Partners Finance
Corporation, the Guarantors named therein and U.S. Bank National Association, as supplemented 

  

	4.	 Indenture dated as of September 14, 2015, among Targa Resources Partners LP, Targa Resources Finance
Corporation, the Guarantors named therein and U.S. Bank National Association, as supplemented 

  

	5.	 Indenture dated as of October 6, 2016, among Targa Resources Partners LP, Targa Resources Finance
Corporation, the Guarantors named therein and U.S. Bank National Association, as supplemented 

  

	6.	 Indenture dated as of October 17, 2017, among Targa Resources Partners LP, Targa Resources Finance
Corporation, the Guarantors named therein and U.S. Bank National Association, as supplemented 

  

	7.	 Indenture dated as of April 12, 2018, among Targa Resources Partners LP, Targa Resources Finance
Corporation, the Guarantors named therein and U.S. Bank National Association, as supplemented 

  

	8.	 Indenture dated as of January 17, 2019, among Targa Resources Partners LP, Targa Resources Finance
Corporation, the Guarantors named therein and U.S. Bank National Association, as supplemented 

  

	9.	 Indenture dated as of November 27, 2019, among Targa Resources Partners LP, Targa Resources Finance
Corporation, the Guarantors named therein and U.S. Bank National Association 

  
 Annex B-1 

 ANNEX C 
  

	1.	 Each of the Issuers and the Non-Excluded Guarantors has been duly
incorporated or formed, as the case may be, under the laws of its jurisdiction of incorporation or formation, as the case may be. 

  

	2.	 Each of the Issuers and the Covered Guarantors is validly existing as a limited partnership, limited liability
company or corporation, as applicable, and is in good standing under the laws of its jurisdiction of formation or incorporation, as applicable, and has all requisite limited partnership, limited liability company or corporate power and authority, as
applicable, necessary to own or lease its properties and to conduct its business, in each case as described in the Pricing Disclosure Package and the Final Memorandum in all material respects. 

 

	3.	 The Partnership has the authorized, issued and outstanding capitalization set forth in the Pricing Disclosure
Package and the Final Memorandum as of the dates specified therein; all of the issued and outstanding equity interests (other than general partner interests) of each of the Issuers and the Non-Excluded
Guarantors have been duly authorized and validly issued (in accordance with the organizational documents of each such entity), are fully paid (in the case of an interest in a limited partnership or limited liability company, to the extent required
under the organizational documents of such entity) and nonassessable (except as such nonassessability may be affected by Sections 17-607 and 17-804 of the Delaware LP
Act, Sections 18-607 and 18-804 of the Delaware LLC Act or Sections 153.102, 153.103, 153.202 and 153.210 of the TBOC, as applicable) and, to the knowledge of such
counsel, were not issued in violation of any preemptive or similar right; all of the issued and outstanding equity interests of Finance Co and each Non-Excluded Guarantor are owned, directly or indirectly, by
the Partnership, free and clear of all Liens (other than (i) those created by or arising under the Delaware General Corporation Law, the Delaware LLC Act or the Delaware LP Act, as the case may be; (ii) restrictions on transferability and
other Liens described in the Pricing Disclosure Package, the Final Memorandum or the organizational documents; (iii) those arising pursuant to or permitted under the Partnership Credit Agreement; and (iv) those imposed by the Act and the
securities or “Blue Sky” laws of certain jurisdictions) (A) in respect of which a financing statement under the Uniform Commercial Code of the State of Delaware naming the Partnership as debtor or, in the case of equity interests of a
Non-Excluded Guarantor owned directly by one or more other Non-Excluded Guarantors, naming any such other Non-Excluded Guarantors
as debtor(s), is on file as of a recent date in the office of the Secretary of State of the State of Delaware or (B) otherwise known to such counsel, without independent investigation). 

 

	4.	 The Issuers and each Covered Guarantor have all requisite corporate, limited partnership or limited liability
company power and authority, as applicable, to execute, deliver and perform each of their obligations under the Indenture, the Notes, the Exchange Notes and the Private Exchange Notes (each as defined in the Registration Rights Agreement); the
Indenture meets the requirements for qualification under the TIA; the Indenture has been duly and validly authorized by the Issuers and each Covered Guarantor and, when duly executed and delivered by the Issuers and each Covered Guarantor (assuming
the due 

  
 Annex C-1 

	 	
authorization, execution and delivery thereof by the Trustee and SouthOk), will constitute the valid and legally binding agreement of the Issuers and each Guarantor, enforceable against the
Issuers and each Guarantor in accordance with its terms, except that the enforcement thereof may be subject to the Enforceability Exceptions. 

  

	5.	 The Notes have each been duly and validly authorized by the Issuers and, when duly executed and delivered by
the Issuers and paid for by the Initial Purchasers in accordance with the terms of this Agreement (assuming the due authorization, execution and delivery of the Indenture by the Trustee and due authentication and delivery of the Notes by the Trustee
in accordance with the Indenture), will constitute the valid and legally binding obligations of the Issuers, entitled to the benefits of the Indenture, and enforceable against the Issuers in accordance with their terms, except that the enforcement
thereof may be subject to the Enforceability Exceptions. 

  

	6.	 The Guarantees have been duly and validly authorized by the Covered Guarantors and when the Notes have been
paid for by the Initial Purchasers in accordance with the terms of this Agreement (assuming the due authorization, execution and delivery of the Indenture by the Trustee and SouthOk and the due authentication of the Notes by the Trustee in
accordance with the Indenture), will constitute the valid and legally binding obligations of the Guarantors, entitled to the benefits of the Indenture, and enforceable against the Guarantors in accordance with their terms, except that the
enforcement thereof may be subject to the Enforceability Exceptions. 

  

	7.	 The Exchange Notes and the Private Exchange Notes have been duly and validly authorized by the Issuers, and if
and when the Exchange Notes and the Private Exchange Notes are duly executed and delivered by the Issuers in accordance with the terms of the Registration Rights Agreement and the Indenture (assuming the due authorization, execution and delivery of
the Indenture by the Trustee and due authentication and delivery of the Exchange Notes and the Private Exchange Notes by the Trustee in accordance with the Indenture), will constitute the valid and legally binding obligations of the Issuers,
entitled to the benefits of the Indenture, and enforceable against the Issuers in accordance with their terms, except that the enforcement thereof may be subject to the Enforceability Exceptions. 

 

	8.	 The Issuers and the Covered Guarantors have all requisite partnership, limited liability company or corporate
power and authority to execute, deliver and perform their obligations under the Registration Rights Agreement; the Registration Rights Agreement has been duly and validly authorized by the Issuers and the Covered Guarantors and, when duly executed
and delivered by the Issuers and the Covered Guarantors (assuming due authorization, execution and delivery thereof by the Initial Purchasers and SouthOk), will constitute the valid and legally binding agreement of the Issuers and the Guarantors,
enforceable against the Issuers and the Guarantors in accordance with its terms, except that (A) the enforcement thereof may be subject to the Enforceability Exceptions and (B) any rights to indemnity or contribution thereunder may be
limited by federal and state securities laws and public policy considerations. 

  
 Annex C-2 

	9.	 The Issuers and the Covered Guarantors have all requisite corporate, partnership or limited liability company
power and authority, as applicable, to execute, deliver and perform their obligations under this Agreement and to consummate the transactions contemplated hereby; this Agreement and the consummation by the Issuers and the Covered Guarantors of the
transactions contemplated hereby have been duly and validly authorized by the Issuers and the Covered Guarantors. This Agreement has been duly executed and delivered by the Issuers and the Covered Guarantors. 

 

	10.	 (a) The descriptions of the Indenture, the Notes and the Registration Rights Agreement contained in the Pricing
Disclosure Package and the Final Memorandum are accurate in all material respects, and (b) the statements under the caption “Certain United States Federal Income Tax Considerations” in the Pricing Disclosure Package and the Final
Memorandum insofar as they purport to constitute a summary of United States federal tax law and regulations or legal conclusions with respect thereto, constitute accurate summaries of the matters described therein in all material respects, subject
to the assumptions and qualifications set forth therein. 

  

	11.	 The execution, delivery and performance of this Agreement, the Indenture, the Registration Rights Agreement and
the consummation of the transactions contemplated hereby and thereby (including, without limitation, the issuance and sale of the Notes to the Initial Purchasers) will not constitute or result in a breach or a default under (or an event that with
notice or passage of time or both would constitute a default under) any of (i) the terms or provisions of any Contract listed on Annex B hereto, (ii) the organizational documents of any of the Issuers or the Covered Guarantors, or
(iii) any statute, judgment, decree, order, rule or regulation (excluding any securities laws, rules or regulations) known to such counsel to be applicable to the Issuers or any of the Covered Guarantors or any of their respective properties or
assets, except, with respect to clauses (i) and (iii) only, for any such conflict, breach or violation that could not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect. 

 

	12.	 No consent, approval, authorization or order of any governmental authority is required for the issuance and
sale by the Issuers of the Notes to the Initial Purchasers or the consummation by the Issuers of the other transactions contemplated hereby, except such as may be required under securities laws, as to which such counsel need express no opinion in
this paragraph, and those which have previously been obtained. 

  

	13.	 None of the Issuers or the Covered Guarantors is, or immediately after the sale of the Notes to be sold
hereunder and the application of the proceeds from such sale (as described in the Pricing Disclosure Package and the Final Memorandum under the caption “Use of Proceeds”) will be, an “investment company” as such term is defined
in the Investment Company Act of 1940, as amended. 

  

	14.	 No registration under the Act of the Notes is required in connection with the sale of the Notes to the Initial
Purchasers or in connection with the initial resale of the Notes by the Initial Purchasers, in each case, as contemplated by this Agreement and the Pricing Disclosure Package and the Final Memorandum, and prior to the commencement of the Exchange
Offer (as defined in the Registration Rights Agreement) or the effectiveness of the Shelf Registration Statement (as defined in the Registration Rights Agreement), the Indenture is not required to be qualified under the TIA.

  
 Annex C-3 

 At the time the foregoing opinion is delivered, Vinson & Elkins L.L.P. shall additionally state
that it has participated in conferences with officers and other representatives of the Issuers, representatives of the independent registered public accountants for the Issuers, representatives of the Initial Purchasers and counsel for the Initial
Purchasers, at which conferences the contents of the Pricing Disclosure Package and the Final Memorandum and related matters were discussed, and, although it has not independently verified, and is not passing on and assumes no responsibility for the
accuracy, completeness or fairness of the statements contained in the Pricing Disclosure Package and the Final Memorandum (except to the extent specified in subsection 7(a)(x)), no facts have come to its attention which lead it to believe that
the Pricing Disclosure Package, as of the Time of Execution or at the Closing Date, or that the Final Memorandum, as of its date or at the Closing Date, contained an untrue statement of a material fact or omitted to state a material fact necessary
to make the statements contained therein, in light of the circumstances under which they were made, not misleading (it being understood that such firm need make no comment with respect to the financial statements and related notes thereto and the
other financial and accounting data derived from the Issuers’ books and records included in the Pricing Disclosure Package or the Final Memorandum). 

The opinion and advice of Vinson & Elkins L.L.P. described in this Annex C shall be rendered to the Initial Purchasers at the request of the
Partnership and shall so state therein. 

  
 Annex C-4Exhibit
10.1

 

PLACEMENT
AGENCY AGREEMENT

 

August
16, 2020

 

ThinkEquity,
a division of

Fordham
Financial Management, Inc.

17
State Street, 22nd Floor

New
York, NY 10004

 

Torreya
Capital, LLC

555
Madison Avenue, Suite 1201

New
York • NY 10022

 

Ladies
and Gentlemen:

 

Introductory.
This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of
Fordham Financial Management, Inc., and Torreya Capital, LLC (together, the “Placement Agents”) shall be engaged
by Oncosec Medical Incorporated, a Nevada corporation (the “Company”), to act as the exclusive Placement Agents
in connection with the offering (hereinafter referred to as the “Offering”) of shares of the common stock,
par value $.0001 per share (the “Shares”) of the Company, as more fully described below. Capitalized terms
used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement (defined below).

 

1.
Agreement to Act as Placement Agents; Closing;
Placement Agent Compensation.

 

1.1
On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and
conditions of this Agreement between the Company and the Placement Agents, the Placement Agents are appointed as the Company’s
exclusive placement agents regarding the Offering. On the basis of such representations and warranties and subject to such terms
and conditions, the Placement Agents hereby accept such appointment and agree to perform the services hereunder diligently and
in good faith and in a professional and businesslike manner and to use their best efforts to assist the Company in finding subscribers
of the Shares and to complete the Offering. The Placement Agents have no obligation to purchase any of the Shares. Unless sooner
terminated in accordance with this Agreement, the engagement of the Placement Agents hereunder shall continue until the later
of the termination of the Offering by the Company or the Closing. The Offering will be made on a “best efforts” basis.
The Placement Agents may retain other brokers or dealers to act as sub-placement agents on their behalf in connection with the
Offering, with any fees they may be entitled to being paid out of the fee paid to the Placement Agents pursuant to Section 1.6.

 

1.2
The Shares are being sold to the Buyers and the Other Investors pursuant to a Securities Purchase Agreement dated the date hereof
(the “Securities Purchase Agreement”) at the following initial public offering price: $3.25 per Common Share
(the “Public Offering Price”).

 

1.3
Payment of the purchase price equal to the Public Offering Price less the Cash Fee (the “Purchase Price”) for,
and delivery of, the Securities (the “Closing”) shall be made at the offices of Loeb & Loeb LLP (“Placement
Agent Counsel”), 345 Park Avenue, New York, NY 10154, or at such other place as shall be agreed upon by the Placement
Agents and the Company, at 10:00 a.m. (New York City time) on August 19, 2020, or such other time not later than ten Business
Days after such date as shall be agreed upon by the Placement Agents and the Company (such time and date of payment and delivery
being herein called “Closing Date”). The term “Business Day” means any day other than a
Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New
York, New York.

 

    	 

    	 

    

 

1.4
On the Closing Date, (i) the Purchase Price will be released to the Company either (a) by the Placement Agents on behalf of each
Buyer or Other Investor for the Shares to be issued and sold to such Buyer or Other Investor at the Closing, by wire transfer
of immediately available funds in accordance with the flow of funds letter regarding the Closing, or (b) by the Buyer or Other
Investor wiring the Purchase Price to the Company by wire transfer to an account designated in writing by the Company, and (ii)
the Company shall (A) cause Nevada Agency and Transfer Company (together with any subsequent transfer agent, the “Transfer
Agent”) through the Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program,
to credit such aggregate number of Shares that each Buyer is purchasing as is set forth opposite such Buyer’s name in column
(2) of the Schedule of Buyers and as identified by each Buyer in the Purchaser Signature Page attached to the Securities Purchase
Agreement or opposite such Other Investor’s name as set forth in the flow of funds letter regarding the Closing to either
(a) the Placement Agents’ balance account with DTC through its Deposit/Withdrawal at Custodian system, or (b) directly to
the account of each Buyer or Other Investor, or its respective nominee(s), at the designated account with DTC as provided on the
Purchaser Signature Page or flow of funds letter (if applicable). All actions taken at the Closing shall be deemed to have occurred
simultaneously on the Closing Date. Any Shares for which payment has not been received by the Company, to the extent they have
been delivered to the Placement Agents or any such Buyer or Other Investor, shall be returned to the Company.

 

1.5
No Shares which the Company has agreed to sell pursuant to this Agreement shall be deemed to have been purchased and paid for,
or issued and sold by the Company, until the appropriate corresponding number of Shares shall have been delivered to the Buyers,
Other Investors or the Placement Agents via DTC against payment therefor. If the Company shall default in its obligations to deliver
the Shares to the Buyers or Other Investors or the Placement Agents on behalf of such Buyers or Other Investors as per such instructions,
the Company shall indemnify and hold the Placement Agents harmless against any loss, claim, damage or liability directly or indirectly
arising from or as a result of such default by the Company.

 

1.6
As compensation for services rendered, on the Closing Date, the Company shall pay to the Placement Agents a cash fee (the “Cash
Fee”) equal to 8% of the aggregate purchase price paid by the Buyers and the Other Investors in respect of the Shares
purchased at the Closing, which shall be deducted from the Purchase Price payable at Closing, provided, however, that the Company
shall be permitted to direct up to 1.5% of the aggregate purchase price paid by the Buyers and the Other Investors in respect
of the Shares purchased at the Closing to be paid out of the Cash Fee to other broker dealers at its sole discretion.

 

1.7
The Company hereby acknowledges that (i) the Offering, including the determination of the offering price of the Shares and any
related discounts, commissions and fees, shall be an arm’s-length commercial transaction between the Company and the Buyers
and the Other Investors, (ii) the Placement Agents will be acting as independent contractors and will not be the agent or fiduciary
of the Company or its shareholders, creditors, employees, the Buyers, the Other Investors or any other party, (iii) the Placement
Agents shall not assume an advisory or fiduciary responsibility in favor of the Company (irrespective of whether the Placement
Agents have advised or are currently advising the Company on other matters) and the Placement Agents shall not have any obligation
to the Company with respect to the Offering, except as may be set forth expressly herein, (iv) the Placement Agents and their
respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company
and (v) the Placement Agents will not provide any legal, accounting, regulatory or tax advice with respect to the Offering, and
the Company shall consult its own legal, accounting, regulatory and tax advisors to the extent it deems appropriate.

 

    	- 2 -

    	 

    

 

1.8
The Company is and will be solely responsible for the contents of any and all written or oral communications provided to the Buyers
and the Other Investors regarding the Offering or the Shares; and the Company recognizes that the Placement Agents, in acting
pursuant to this Agreement, will be using information provided by the Company and its agents and representatives and the Placement
Agents assume no responsibility for, and may rely, without independent verification, on the accuracy and completeness of any such
information.

 

1.9
The Company agrees that any information or advice rendered by the Placement Agents or any of their respective representatives
in connection with this engagement is for the confidential use of the Board of Directors of the Company (the “Board”)
only and the Company will not, and will not permit any third party to, disclose or otherwise refer to such advice or information,
in any manner without the Placement Agents’ prior written consent.

 

2.
Representations and Warranties of the Company.
The Company represents and warrants to the Placement Agents and each Other Investor as of the Applicable Time (as defined below),
as of the Closing Date as follows:

 

2.1
Filing of Registration Statement.

 

2.1.1
Pursuant to the Securities Act. The Company has filed with the U.S. Securities and Exchange Commission (the “Commission”)
a “shelf” registration statement on Form S-3 (File No. 333-233447), including any related prospectus or prospectuses,
for the registration of the Shares under the Securities Act of 1933, as amended (the “Securities Act”), which
registration statement was prepared by the Company in all material respects in conformity with the requirements of the Securities
Act and the rules and regulations of the Commission under the Securities Act (the “Securities Act Regulations”)
and contains and will contain all material statements that are required to be stated therein in accordance with the Securities
Act and the Securities Act Regulations. Except as the context may otherwise require, such registration statement on file with
the Commission at any given time, including any amendments thereto to such time, exhibits and schedules thereto at such time,
documents filed as a part thereof or incorporated pursuant to Item 12 of Form S-3 under the Securities Act at such time and the
documents and information otherwise deemed to be a part thereof or included therein pursuant to Rule 430B of the Securities Act
Regulations (the “Rule 430B Information”) or otherwise pursuant to the Securities Act Regulations at such time,
is referred to herein as the “Registration Statement.” The Registration Statement at the time it originally
became effective is referred to herein as the “Initial Registration Statement.” If the Company files any registration
statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term “Registration Statement”
shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement was declared effective by
the Commission on April 20, 2017 (the “Effective Date”).

 

The
prospectus in the form in which it was filed with the Commission in connection with the Initial Registration Statement is herein
called the “Base Prospectus.” Each preliminary prospectus supplement to the Base Prospectus (including the
Base Prospectus as so supplemented) that described the Shares and the Offering and omitted the Rule 430B Information and that
was used prior to the filing of the final prospectus supplement referred to in the following paragraph is herein called a “Preliminary
Prospectus.”

 

Promptly
after the execution and delivery of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement
to the Base Prospectus relating to the Shares and the Offering in accordance with the provisions of Rule 430B and Rule 424(b)
of the Securities Act Regulations. Such final prospectus supplement (including the Base Prospectus as so supplemented), in the
form filed with the Commission pursuant to Rule 424(b) under the Securities Act is herein called the “Prospectus.”
Any reference herein to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include
the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act as of the date of such
prospectus.

 

    	- 3 -

    	 

    

 

“Applicable
Time” means 8:00 p.m., Eastern time, on August 16, 2020.

 

“Disclosure
Package” means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time.

 

“Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the Securities
Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined
in Rule 405 of the Securities Act Regulations) relating to the Shares that is (i) required to be filed with the Commission by
the Company, (ii) a “road show that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or
not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because
it contains a description of the Shares or of the Offering that does not reflect the final terms, in each case in the form filed
or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records
pursuant to Rule 433(g).

 

“Issuer
General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution
to prospective investors (other than a “bona fide electronic road show,” as defined in Rule 433), as evidenced
by its being specified in Schedule 2-B hereto.

 

“Issuer
Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free
Writing Prospectus.

 

2.1.2
Pursuant to the Exchange Act. The Company has filed with the Commission a Form 8-A (Accession No. 001-37405) providing
for the registration pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
of the shares of Common Stock. The registration of the shares of Common Stock and related Form 8-A have become effective under
the Exchange Act on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the shares of Common Stock under the Exchange Act, nor has the Company received any notification
that the Commission is contemplating terminating such registration.

 

2.2
Stock Exchange Listing. The shares of Common Stock have been approved for listing on The Nasdaq Capital Market (the “Exchange”),
and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the
Exchange, nor has the Company received any notification that the Exchange is contemplating terminating such listing except as
described in the Registration Statement, the Disclosure Package and the Prospectus. The Company has submitted the Listing of Additional
Shares application with the Exchange with respect to the Offering of the Shares.

 

2.3
No Stop Orders, etc. Neither the Commission nor, to the Company’s knowledge, any state regulatory authority has issued
any order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has
instituted or, to the Company’s knowledge, threatened to institute, any proceedings with respect to such an order. The Company
has complied with each request (if any) from the Commission for additional information.

 

    	- 4 -

    	 

    

 

2.4
Disclosures in Registration Statement.

 

2.4.1
Compliance with Securities Act and 10b-5 Representation.

 

(i)
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective (including each deemed
effective date with respect to the Placement Agents pursuant to Rule 430B or otherwise under the Securities Act) complied and
will comply in all material respects with the requirements of the Securities Act and the Securities Act Regulations. The conditions
for use of Form S-3, set forth in the General Instructions thereto, including, but not limited to, General Instruction I.B.6 and
other conditions related to the offer and sale of the Shares, have been satisfied. Each Preliminary Prospectus and the Prospectus,
at the time each was or will be filed with the Commission, complied and will comply in all material respects with the requirements
of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Placement Agents for use
in connection with this Offering and the Prospectus was or will be identical to the electronically transmitted copies thereof
filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

 

(ii)
Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time or at the Closing
Date contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading.

 

(iii)
The Disclosure Package, as of the Applicable Time, at the Closing Date, did not, does not and will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and any Issuer Limited Use Free Writing Prospectus hereto does not conflict with the
information contained in the Registration Statement, any Preliminary Prospectus or the Prospectus, and each such Issuer Limited
Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus as of the Applicable Time, did not include
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading.

 

(iv)
Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the
time of any filing with the Commission pursuant to Rule 424(b), at the Closing Date, included, includes or will include an untrue
statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this
representation and warranty shall not apply to the Placement Agents’ Information.

 

(v)
The documents incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, when they became
effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the
Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and none of such
documents contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and
any further documents so filed and incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus,
when such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects
to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission
thereunder, and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

    	- 5 -

    	 

    

 

2.4.2
Disclosure of Agreements. The agreements and documents described in the Registration Statement, the Disclosure Package
and the Prospectus conform in all material respects to the descriptions thereof contained or incorporated by reference therein
and there are no agreements or other documents required by the Securities Act and the Securities Act Regulations to be described
in the Registration Statement, the Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the
Registration Statement or to be incorporated by reference in the Registration Statement, the Disclosure Package or the Prospectus,
that have not been so described or filed or incorporated by reference. Each agreement or other instrument (however characterized
or described) to which the Company is a party or by which it is or may be bound or affected and (i) that is referred to or incorporated
by reference in the Registration Statement, the Disclosure Package and the Prospectus, or (ii) is material to the Company’s
business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and
is enforceable against the Company and, to the Company’s knowledge, the other parties thereto, in accordance with its terms,
except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’
rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and
state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may
be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. None
of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the best of the Company’s
knowledge, any other party is in default thereunder and, to the best of the Company’s knowledge, no event has occurred that,
with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the Company’s knowledge,
performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any
existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign,
having jurisdiction over the Company or any of its assets or businesses (each, a “Governmental Entity”), including,
without limitation, those relating to environmental laws and regulations.

 

2.4.3
Prior Securities Transactions. No securities of the Company have been sold by the Company or by or on behalf of, or for
the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed
in the Registration Statement, the Disclosure Package and the Preliminary Prospectus.

 

2.4.4
Regulations. The disclosures in the Registration Statement, the Disclosure Package and the Prospectus concerning the effects
of federal, state, local and all foreign regulation on the Offering and the Company’s business as currently contemplated
are correct in all material respects and no other such regulations are required to be disclosed in the Registration Statement,
the Disclosure Package and the Prospectus which are not so disclosed.

 

2.4.5
No Other Distribution of Offering Materials. The Company has not, directly or indirectly, distributed and will not distribute
any offering material in connection with the Offering other than any Preliminary Prospectus, the Disclosure Package, the Prospectus
and other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.

 

2.5
Changes After Dates in Registration Statement.

 

2.5.1
No Material Adverse Change. Since the respective dates as of which information is given in the Registration Statement,
the Disclosure Package and the Prospectus: (i) there has been no material adverse change in the financial position or results
of operations of the Company, nor any change or development that, singularly or in the aggregate, would have or reasonably be
expected to result in a material adverse change or a prospective material adverse change, in or affecting the condition (financial
or otherwise), results of operations, business, assets or prospects of the Company (a “Material Adverse Change”);
(ii) there have been no material transactions entered into by the Company, other than as contemplated pursuant to this Agreement;
and (iii) no officer or director of the Company has resigned from any position with the Company except as disclosed therein.

 

    	- 6 -

    	 

    

 

2.5.2
Recent Securities Transactions, etc. Subsequent to the respective dates as of which information is given in the Registration
Statement, the Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed
in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred
any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other
distribution on or in respect to its capital stock.

 

2.6
Disclosures in Commission Filings. Since January 1, 2018, (i) none of the Company’s filings with the Commission contained
any untrue statement of a material fact or omitted to state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and (ii) the Company has made all filings with the
Commission required under the Exchange Act and the rules and regulations of the Commission promulgated thereunder (the “Exchange
Act Regulations”).

 

2.7
Independent Accountants. To the knowledge of the Company, Mayer Hoffman McCann P.C. (the “Auditors”),
whose respective reports are filed with the Commission and included or incorporated by reference in the Registration Statement,
the Disclosure Package and the Prospectus, is each an independent registered public accounting firm as required by the Securities
Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. The Auditors have not, during the periods
covered by the financial statements included or incorporated by reference in the Registration Statement, the Disclosure Package
and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.

 

2.8
Financial Statements, etc. The financial statements, including the notes thereto and supporting schedules included or incorporated
by reference in the Registration Statement, the Disclosure Package and the Prospectus, fairly present the financial position and
the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have
been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), consistently applied
throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments
that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules
included or incorporated by reference in the Registration Statement present fairly the information required to be stated therein.
No other historical or pro forma financial statements or supporting schedules are required to be included in the Registration
Statement, the Disclosure Package or the Prospectus by the Securities Act or the Securities Act Regulations. The pro forma financial
statements and the related notes, if any, included or incorporated by reference in the Registration Statement, the Disclosure
Package and the Prospectus have been properly compiled and prepared in accordance with the applicable requirements of the Securities
Act, the Securities Act Regulations, the Exchange Act or the Exchange Act Regulations and present fairly the information shown
therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to
give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement,
the Disclosure Package or the Prospectus, or incorporated or deemed incorporated by reference therein, regarding “non-GAAP
financial measures” (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation
G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration
Statement, the Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations
(including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that
may have a material current or future effect on the Company’s financial condition, changes in financial condition, results
of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as
disclosed in the Registration Statement, the Disclosure Package and the Prospectus, (a) neither the Company nor any of its direct
and indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Disclosure Package
and the Prospectus as being a subsidiary of the Company (each, a “Subsidiary” and, collectively, the “Subsidiaries”),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than
in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind
with respect to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries,
or, other than in the course of business or any grants under any stock compensation plan, and (d) there has not been any Material
Adverse Change in the Company’s long-term or short-term debt.

 

    	- 7 -

    	 

    

 

2.9
Authorized Capital; Options, etc. The Company had, at the date or dates indicated in the Registration Statement, the Disclosure
Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions
stated in the Registration Statement, the Disclosure Package and the Prospectus, the Company will have on the Closing Date the
adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Disclosure
Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date, there will be no stock options,
warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the Company
or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts or commitments to issue
or sell shares of Common Stock or any such options, warrants, rights or convertible securities.

 

2.10
Valid Issuance of Securities, etc.

 

2.10.1
Outstanding Securities. All issued and outstanding securities of the Company issued prior to the transactions contemplated
by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have
no rights of rescission or similar rights with respect thereto or put rights, and are not subject to personal liability by reason
of being such holders; and none of such securities were issued in violation of the preemptive rights, rights of first refusal
or rights of participation of any holders of any security of the Company or similar contractual rights granted by the Company.
The authorized shares of Common Stock conform in all material respects to all statements relating thereto contained in the Registration
Statement, the Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock were at all
relevant times either registered under the Securities Act and the applicable state securities or “blue sky” laws or,
based in part on the representations and warranties of the purchasers of such Shares, exempt from such registration requirements.

 

2.10.2
Securities Sold Pursuant to this Agreement. The Shares have been duly authorized for issuance and sale and, when issued
and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal
liability by reason of being such holders; the Shares are not and will not be subject to the preemptive rights of any holders
of any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken
for the authorization, issuance and sale of the Shares has been duly and validly taken. The Shares conform in all material respects
to all statements with respect thereto contained in the Registration Statement, the Disclosure Package and the Prospectus.

 

2.11
Registration Rights of Third Parties. As of the Applicable time and immediately prior to the Closing, no holders of any
securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the
right to require the Company to register any such securities of the Company under the Securities Act or to include any such securities
in a registration statement to be filed by the Company other than as described in the Registration Statement, the Disclosure Package
and the Prospectus.

 

    	- 8 -

    	 

    

 

2.12
Validity and Binding Effect of Agreements. Each of this Agreement and the Securities Purchase Agreement has been duly and
validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreement of the Company,
enforceable against the Company in accordance with its terms, except: (i) as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting creditors’ rights generally; (ii) as enforceability of any indemnification
or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance
and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court
before which any proceeding therefor may be brought.

 

2.13
No Conflicts, etc. The execution, delivery and performance by the Company of this Agreement and all ancillary documents,
the consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the
terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in
a material breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result in
the creation, modification, termination or imposition of any lien, charge, mortgage, pledge, security interest, claim, equity,
trust or other encumbrance, preferential arrangement, defect or restriction of any kind whatsoever or encumbrance upon any property
or assets of the Company pursuant to the terms of any indenture, mortgage, deed of trust, note, lease, loan agreement or any other
agreement or instrument, franchise, license or permit to which the Company is a party or as to which any property of the Company
is a party; (ii) result in any violation of the provisions of the Company’s Articles of Incorporation (as the same may be
amended or restated from time to time, the “Charter”) or the by-laws of the Company (as the same may be amended
or restated from time to time, the “Bylaws”); or (iii) violate any existing applicable law, rule, regulation,
judgment, order or decree of any Governmental Entity as of the date hereof (including, without limitation, those promulgated by
the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or by any
foreign, federal, state or local regulatory authority performing functions similar to those performed by the FDA).

 

2.14
No Defaults; Violations. No material default exists in the due performance and observance of any term, covenant or condition
of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement
or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company
is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company
is not in violation of any term or provision of its Charter or by-laws, or in violation of any franchise, license, permit, applicable
law, rule, regulation, judgment or decree of any Governmental Entity.

 

2.15
Corporate Power; Licenses; Consents.

 

2.15.1
Conduct of Business. The Company has all requisite corporate power and authority, and has all necessary authorizations,
approvals, orders, licenses, certificates and permits of and from all governmental regulatory officials and bodies that it needs
as of the date hereof to conduct its business purpose as described in the Registration Statement, the Disclosure Package and the
Prospectus.

 

2.15.2
Transactions Contemplated Herein. The Company has all corporate power and authority to enter into this Agreement and to
carry out the provisions and conditions hereof, and all consents, authorizations, approvals and orders required in connection
therewith have been obtained. No consent, authorization or order of, and no filing with, any court, government agency or other
body is required for the valid issuance, sale and delivery of the Shares and the consummation of the transactions and agreements
contemplated by this Agreement and as contemplated by the Registration Statement, the Disclosure Package and the Prospectus, except
with respect to applicable federal and state securities laws and the rules and regulations of the Exchange and the Financial Industry
Regulatory Authority, Inc. (“FINRA”).

 

    	- 9 -

    	 

    

 

2.16
D&O Questionnaires. To the Company’s knowledge, all information contained in the questionnaires (the “Questionnaires”)
completed by each of the Company’s directors and officers immediately prior to the Offering (the “Insiders”),
as supplemented by all information concerning the Company’s directors, officers and principal shareholders as described
in the Registration Statement, the Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in Section
2.27 below) provided to the Placement Agents, is true and correct in all material respects and the Company has not become aware
of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.

 

2.17
Litigation; Governmental Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation
or governmental proceeding pending or, to the Company’s knowledge, threatened against, or involving the Company or, to the
Company’s knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Disclosure
Package and the Prospectus, or in connection with the Company’s listing application for the listing of the Shares on the
Exchange, and which is required to be disclosed in the Company’s filings with the SEC.

 

2.18
Good Standing. The Company has been duly incorporated and is validly existing as a corporation and is in good standing
under the laws of the State of Nevada as of the date hereof, and is duly qualified to do business and is in good standing in each
other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except
where the failure to be so qualified or in good standing, singularly or in the aggregate, would not have or reasonably be expected
to result in a Material Adverse Change.

 

2.19
Insurance. The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and
covering such risks which the Company believes are adequate, including, but not limited to, directors and officers insurance coverage
at least equal to $5,000,000, and all such insurance is in full force and effect. The Company has no reason to believe that it
will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would
not result in a Material Adverse Change.

 

2.20
Transactions Affecting Disclosure to FINRA.

 

2.20.1
Finder’s Fees. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, there
are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder’s, consulting or
origination fee by the Company or any Insider with respect to the sale of the Shares hereunder or any other arrangements, agreements
or understandings of the Company or, to the Company’s knowledge, any of its shareholders that may affect the Placement Agents’
compensation, as determined by FINRA.

 

2.20.2
Payments Within Twelve Months. Except for payments made to the Placement Agents and except as described in the Registration
Statement, the Disclosure Package and the Prospectus, the Company has not made any direct or indirect payments (in cash, securities
or otherwise) to: (i) any person, as a finder’s fee, consulting fee or otherwise, in consideration of such person raising
capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member;
or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve
months prior to the date of this Agreement, other than the payment to the Placement Agents as provided hereunder in connection
with the Offering.

 

2.20.3
Use of Proceeds. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member
or its affiliates, except as specifically authorized herein.

 

    	- 10 -

    	 

    

 

2.20.4
FINRA Affiliation. There is no (i) officer or director of the Company, (ii) beneficial owner of 5% or more of any class
of the Company’s securities or (iii) beneficial owner of the Company’s unregistered equity securities which were acquired
during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person
of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA). Except
as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company (i) does not have any material
lending or other relationship with any bank or lending affiliate of the Placement Agents and (ii) does not intend to use any of
the proceeds from the sale of the Shares to repay any outstanding debt owed to any affiliate of the Placement Agents.

 

2.20.5
Information. All information provided by the Company to Placement Agent Counsel specifically for use by Placement Agent
Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete
in all material respects.

 

2.21
Foreign Corrupt Practices Act. None of the Company and its Subsidiaries or, to the Company’s knowledge, any director,
officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company
and its Subsidiaries, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal
price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer
or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or
any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help
or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i) might subject
the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the
past, might have had a Material Adverse Change; (iii) if not continued in the future, might adversely affect the assets, business,
operations or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures
are sufficient to cause the Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended,
and the rules and regulations thereunder (collectively, the “FCPA”) or employee; (iv) violated or is in violation
of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation; (v) made any bribe, rebate, payoff,
influence payment, kickback or other unlawful payment; or (vi) received notice of any investigation, proceeding or inquiry by
any Governmental Entity regarding any of the matters in clauses (i)-(v) above; and the Company and, to the knowledge of the Company,
the Company’s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and
maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith.

 

2.22
Compliance with OFAC. None of the Company and its Subsidiaries or, to the Company’s knowledge, any director, officer,
agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the
Treasury (“OFAC”), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder,
or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity,
for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

 

2.23
Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) contained in either the Registration Statement, Disclosure Package or Prospectus has been made or reaffirmed
without a reasonable basis or has been disclosed other than in good faith.

 

    	- 11 -

    	 

    

 

2.24
Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money
Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company with
respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

 

2.25
Regulatory. (a) All preclinical studies and clinical trials conducted by or on behalf of the Company that are material
to the Company and its Subsidiaries, taken as a whole, are or have been adequately described in the Registration Statement, the
Disclosure Package and the Prospectus in all material respects. The preclinical studies and clinical trials conducted by or on
behalf of the Company and its Subsidiaries that are described in the Registration Statement, the Disclosure Package and the Prospectus
or the results of which are referred to in the Registration Statement, the Disclosure Package and the Prospectus were and, if
still ongoing, are being conducted in material compliance with all laws and regulations applicable thereto in the jurisdictions
in which they are being conducted and with all laws and regulations applicable to preclinical studies and clinical trials from
which data will be submitted to support marketing approval. The descriptions in the Registration Statement, the Disclosure Package
and the Prospectus of the results of such studies are accurate and complete in all material respects and fairly present the data
derived from such studies, and the Company has no knowledge of, or reason to believe that, any large well-controlled clinical
study the aggregate results of which are inconsistent with or otherwise call into question the results of any clinical study conducted
by or on behalf of the Company that are described in the Registration Statement, the Disclosure Package and the Prospectus or
the results of which are referred to in the Registration Statement, the Disclosure Package and the Prospectus. Except as disclosed
in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not received any written notices or
statements from the FDA, the European Medicines Agency (“EMA”) or any other governmental agency or authority
imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or material modification for or of any
preclinical studies and clinical trials that are described in the Registration Statement, the Disclosure Package and the Prospectus
or the results of which are referred to in the Registration Statement, the Disclosure Package and the Prospectus. Except as disclosed
in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not received any written notices or
statements from the FDA, the EMA or any other governmental agency, and otherwise has no knowledge of, or reason to believe that,
(i) any investigational new drug application for any potential product of the Company is or has been rejected or placed on clinical
hold; and (ii) any license, approval, permit or authorization to conduct any clinical trial of any potential product of the Company
has been, will be or may be suspended, revoked, modified or limited. Neither the Company nor any of its subsidiaries has failed
to file with the FDA or any foreign, federal, state or local governmental or regulatory authority performing functions similar
to those performed by the FDA, any filing, declaration, listing, registration, report or submission that is required to be so
filed. All such filings were in material compliance with applicable laws when filed and no deficiencies have been asserted by
any applicable regulatory authority (including, without limitation, the FDA or any foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA) with respect to any such filings, declarations,
listings, registrations, reports or submissions. To the knowledge of the Company, there are no facts that would be reasonably
likely to result in any warning, untitled or notice of violation letter or Form FDA-483 from the FDA. The Company is not aware
of any studies, tests or trials the results of which the Company believes reasonably call into question (i) the study, test or
trial results of any of its products, (ii) the efficacy or safety of any of its products or (iii) any of the Company’s filings
with any Governmental Entity.

 

    	- 12 -

    	 

    

 

(b)
Regulatory Filings and Permits. The Company and its Subsidiaries have such permits, licenses, clearances, registrations,
exemptions, patents, franchises, certificates of need and other approvals, consents and other authorizations (“Permits”)
issued by the appropriate domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct
the business of the Company, including, without limitation, any Investigational New Drug Application (an “IND”),
Biologics License Application (“BLA”) and/or New Drug Application (an “NDA”), as required
by FDA, the Drug Enforcement Administration (the “DEA”), or any other Permits issued by domestic or foreign
regional, federal, state, or local agencies or bodies engaged in the regulation of pharmaceuticals such as those being developed
by the Company and its Subsidiaries (collectively, the “Regulatory Permits”), except for any of the foregoing
that would not reasonably be expected to, individually or in the aggregate, result in a Material Adverse Change; the Company is
in compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits are
valid and in full force and effect; the Company has not received any notice of proceedings relating to the revocation, termination,
modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of
an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Change; the Company has
not failed to submit to the FDA any IND, BLA or NDA necessary to conduct the business of the Company, any such filings that were
required to be made were in material compliance with applicable laws when filed, and no material deficiencies have been asserted
by the FDA with respect to any such filings or submissions that were made.

 

(c)
Compliance with Health Care Laws. Each of the Company and its Subsidiaries is, and at all times has been, in compliance
in all material respects with all applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause
for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state
or federal health care program. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.), the Public Health Service Act (42 U.S.C. §§ 201 et seq.),
and the regulations promulgated thereunder; (ii) all applicable federal, state, local and all applicable foreign health care related
fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S.
Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.),
the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including
but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance
Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C.
§ 1320a-7), the civil monetary penalties law (42 U.S.C. § 1320a-7a), HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant to such statutes;
(iii) Medicare (Title XVIII of the Social Security Act); (iv) Medicaid (Title XIX of the Social Security Act); (v) the Controlled
Substances Act (21 U.S.C. §§ 801 et seq.) and the regulations promulgated thereunder; and (vi) any and all other applicable
health care laws and regulations. Neither the Company nor, to the knowledge of the Company, any subsidiary has received notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation
of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action is threatened. Neither the Company nor, to the knowledge of the Company, any subsidiary
is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements,
monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental
or regulatory authority. Additionally, neither the Company, its Subsidiaries nor any of its respective employees, officers or
directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical
research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar
action that could reasonably be expected to result in debarment, suspension, or exclusion.

 

    	- 13 -

    	 

    

 

2.26
Officers’ Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to you
or to Placement Agent Counsel shall be deemed a representation and warranty by the Company to the Placement Agents as to the matters
covered thereby.

 

2.27
Lock-Up Agreements. Schedule 1 hereto contains a complete and accurate list of the Company’s officers and directors
(collectively, the “Lock-Up Parties”). The Company has caused each of the Lock-Up Parties to deliver to the
Placement Agents an executed Lock-Up Agreement, in the form attached hereto as Exhibit A (the “Lock-Up Agreement”),
prior to the execution of this Agreement.

 

2.28
Subsidiaries. All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws
of the place of organization or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership
or lease of property or the conduct of business requires such qualification, except where the failure to qualify would not have
a Material Adverse Change. The Company’s ownership and control of each Subsidiary is as described in the Registration Statement,
the Disclosure Package and the Prospectus.

 

2.29
Related Party Transactions.

 

2.29.1
Business Relationships. There are no business relationships or related party transactions involving the Company or any
other person required to be described in the Registration Statement, the Disclosure Package and the Prospectus that have not been
described as required.

 

2.29.2
No Relationships with Customers and Suppliers. No relationship, direct or indirect, exists between or among the Company
on the one hand, and the directors, officers, 5% or greater stockholders, customers or suppliers of the Company or any of the
Company’s affiliates on the other hand, which is required to be described in the Disclosure Package and the Prospectus or
a document incorporated by reference therein and which is not so described.

 

2.29.3
No Unconsolidated Entities. There are no transactions, arrangements or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including, but
not limited to, any structure finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company’s liquidity or the availability of or requirements for its capital resources required to be described
in the Disclosure Package and the Prospectus or a document incorporated by reference therein which have not been described as
required.

 

2.29.4
No Loans or Advances to Affiliates. There are no outstanding loans, advances (except normal advances for business expenses
in the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers
or directors of the Company, any other affiliates of the Company or any of their respective family members, except as disclosed
in the Registration Statement, the Disclosure Package and the Prospectus.

 

2.30
Board of Directors. The Board is comprised of the persons disclosed in the Registration Statement, the Disclosure Package
and the Prospectus. The qualifications of the persons serving as Board members and the overall composition of the Board comply
with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the
“Sarbanes-Oxley Act”) applicable to the Company and the listing rules of the Exchange. At least one member
of the Audit Committee of the Board qualifies as an “audit committee financial expert,” as such term is defined under
Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of the persons serving on the Board qualify
as “independent,” as defined under the listing rules of the Exchange.

 

    	- 14 -

    	 

    

 

2.31
Sarbanes-Oxley Compliance.

 

2.31.1
Disclosure Controls. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the
Company has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under
the Exchange Act Regulations, and such controls and procedures are effective to ensure that all material information concerning
the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company’s Exchange
Act filings and other public disclosure documents.

 

2.31.2
Compliance. The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the
provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and taken reasonable
steps to ensure the Company’s future compliance (not later than the relevant statutory and regulatory deadlines therefor)
with all of the material provisions of the Sarbanes-Oxley Act.

 

2.32
Accounting Controls. The Company and its Subsidiaries maintain systems of “internal control over financial reporting”
(as defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange
Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers,
or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal
accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements
in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s
general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal controls. The Company’s
auditors and the Audit Committee of the Board of the Company have been advised of: (i) all significant deficiencies and material
weaknesses in the design or operation of internal controls over financial reporting which are known to the Company’s management
and that have adversely affected or are reasonably likely to adversely affect the Company’ ability to record, process, summarize
and report financial information; and (ii) any fraud known to the Company’s management, whether or not material, that involves
management or other employees who have a significant role in the Company’s internal controls over financial reporting. Since
the date of the latest audited financial statements included in the Disclosure Package, there has been no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting.

 

2.33
No Investment Company Status. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Disclosure Package and the Prospectus, will not be, required to register
as an “investment company,” as defined in the Investment Company Act of 1940, as amended.

 

2.34
No Labor Disputes. No labor dispute which is reasonably expected to result in a Material Adverse Change with the employees
of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is imminent.

 

    	- 15 -

    	 

    

 

2.35
Intellectual Property Rights. The Company and each of its Subsidiaries owns or possesses or has valid rights to use all
patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights,
licenses, inventions, trade secrets and similar rights (“Intellectual Property Rights”) necessary for the conduct
of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration Statement, the
Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries
necessary for the conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus
will involve or give rise to any infringement of, or license or similar fees (other than license or similar fees described or
contemplated in the Registration Statement, the Disclosure Package and the Prospectus) for, any Intellectual Property Rights of
others. Neither the Company nor any of its Subsidiaries has received any notice alleging any such infringement of, license or
similar fees for, or conflict with, any asserted Intellectual Property Rights of others. Except as would not reasonably be expected
to result, individually or in the aggregate, in a Material Adverse Change, (i) to the knowledge of the Company, there is no infringement,
misappropriation or violation by third parties of any of the Intellectual Property Rights owned by the Company; (ii) there is
no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights
of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable
basis for any such claim, that would, individually or in the aggregate, together with any other claims in this Section 2.35, reasonably
be expected to result in a Material Adverse Change; (iii) the Intellectual Property Rights owned by the Company and, to the knowledge
of the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction
invalid or unenforceable, in whole or in part, and there is no pending or, to the Company’s knowledge, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company
is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together
with any other claims in this Section 2.35, reasonably be expected to result in a Material Adverse Change; (iv) there is no pending
or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates
or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received any
written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim
that would, individually or in the aggregate, together with any other claims in this Section 2.35, reasonably be expected to result
in a Material Adverse Change; and (v) to the Company’s knowledge, no employee of the Company is in or has ever been in violation
in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where
the basis of such violation relates to such employee’s employment with the Company, or actions undertaken by the employee
while employed with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse
Change. To the Company’s knowledge, all material technical information developed by and belonging to the Company which has
not been disclosed in a filed patent application has been kept confidential. The Company is not a party to or bound by any options,
licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be
set forth in the Registration Statement, the Disclosure Package and the Prospectus and are not described therein. The Registration
Statement, the Disclosure Package and the Prospectus contain in all material respects the same description of the matters set
forth in the preceding sentence. None of the technology employed by the Company has been obtained or is being used by the Company
in violation of any contractual obligation binding on the Company or, to the Company’s knowledge, any of its officers, directors
or employees, or otherwise in violation of the rights of any persons.

 

    	- 16 -

    	 

    

 

All
licenses for the use of the Intellectual Property described in the Registration Statement, the Disclosure Package and the Prospectus
are in full force and effect in all material respects and are enforceable by the Company and, to the Company’s knowledge,
the other parties thereto, in accordance with their terms, except (x) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors’ rights generally, (y) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive
and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any
proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company, and the Company has
not, and to the Company’s knowledge, no other party is in default thereunder and no event has occurred that, with the lapse
of time or the giving of notice, or both, would constitute a default thereunder.

 

2.36
Clinical Studies. All preclinical and clinical studies conducted by or on behalf of the Company Parties that are material
to an understanding of the Company’s business and an investment in the Company Parties, are or have been adequately described
in the Registration Statement, the Disclosure Package and the Prospectus in all material respects. To the Company’s knowledge,
after reasonable inquiry, the clinical and preclinical studies conducted by or on behalf of the Company Parties that are described
in the Registration Statement, the Pricing Package and Prospectus or the results of which are referred to in the Registration
Statement, the Disclosure Package and the Prospectus were and, if still ongoing, are being conducted in material compliance with
all laws and regulations applicable thereto in the jurisdictions in which they are being conducted and with all laws and regulations
applicable to preclinical and clinical studies from which data will be submitted to support marketing approval. The descriptions
in the Registration Statement, the Disclosure Package and the Prospectus of the results of such studies are accurate and complete
in all material respects and fairly present the data derived from such studies, and Company has no knowledge of any large well-controlled
clinical study the aggregate results of which are inconsistent with or otherwise call into question the results of any clinical
study conducted by or on behalf of the Company that are described in the Registration Statement, the Disclosure Package and the
Prospectus. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not
received any written notices or statements from the FDA, the European Medicines Agency (“EMA”) or any other
Governmental Entity imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or material modification
for or of any clinical or preclinical studies that are described in the Registration Statement, the Disclosure Package and the
Prospectus or the results of which are referred to in the Registration Statement, the Disclosure Package and the Prospectus, the
Company Parties have not received any written notices or statements from the FDA, the EMA or any other Governmental Entity, and
otherwise has no knowledge or reason to believe, that (i) any investigational new drug application for potential product of the
Company is or has been rejected or determined to be non-approvable or conditionally approvable; and (ii) any license, approval,
permit or authorization to conduct any clinical trial of any potential product of the Company has been, will be or may be suspended,
revoked, modified or limited.

 

2.37
Taxes. Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with
taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company
and its Subsidiaries has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all
taxes imposed on or assessed against the Company or such respective Subsidiary. The provisions for taxes payable, if any, shown
on the financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes,
whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed
in writing to the Placement Agents, (i) no issues have been raised (and are currently pending) by any taxing authority in connection
with any of the returns or taxes asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation
with respect to the returns or collection of taxes have been given by or requested from the Company or its Subsidiaries. The term
“taxes” means all federal, state, local, foreign and other net income, gross income, gross receipts, sales,
use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise,
severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges
of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto.
The term “returns” means all returns, declarations, reports, statements and other documents required to be
filed in respect to taxes.

 

    	- 17 -

    	 

    

 

2.38
ERISA Compliance. The Company and any “employee benefit plan” (as defined under the Employee Retirement Income
Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”))
established or maintained by the Company or its “ERISA Affiliates” (as defined below) are in compliance in all material
respects with ERISA. “ERISA Affiliate” means, with respect to the Company, any member of any group of organizations
described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published
interpretations thereunder (the “Code”) of which the Company is a member. No “reportable event”
(as defined under ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan”
established or maintained by the Company or any of its ERISA Affiliates. No “employee benefit plan” established or
maintained by the Company or any of its ERISA Affiliates, if such “employee benefit plan” were terminated, would have
any “amount of unfunded benefit liabilities” (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates
has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of,
or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each “employee
benefit plan” established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under
Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure
to act, which would cause the loss of such qualification.

 

2.39
Compliance with Laws. The Company: (i) is and at all times has been in compliance with all statutes, rules, or regulations
applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export storage or disposal of any product manufactured or distributed by the
Company (“Applicable Laws”), except as would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Change; (ii) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled
letter or other correspondence or written notice from the FDA or any other governmental authority alleging or asserting noncompliance
with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments
thereto required by any such Applicable Laws (“Authorizations”); (iii) possesses all material Authorizations
and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations;
(iv) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action from any governmental authority or third party alleging that any product operation or activity is in violation
of any Applicable Laws or Authorizations and has no knowledge that any such governmental authority or third party is considering
any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received written notice that any
governmental authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and
has no knowledge that any such governmental authority is considering such action; (vi) has filed, obtained, maintained or submitted
all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required
by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected
or supplemented by a subsequent submission); and (vii) has not, either voluntarily or involuntarily, initiated, conducted, or
issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning,
“dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product
or any alleged product defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends
to initiate any such notice or action.

 

    	- 18 -

    	 

    

 

2.40
Environmental Laws. The Company and its Subsidiaries are in compliance with all foreign, federal, state and local rules,
laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection
of health and safety or the environment which are applicable to their businesses (“Environmental Laws”), except
where the failure to comply would not, singularly or in the aggregate, result in a Material Adverse Change. There has been no
storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic
or other wastes or other hazardous substances by, due to, or caused by the Company or any of its Subsidiaries (or, to the Company’s
knowledge, any other entity for whose acts or omissions the Company or any of its Subsidiaries is or may otherwise be liable)
upon any of the property now or previously owned or leased by the Company or any of its Subsidiaries, or upon any other property,
in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law,
statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability;
and there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding
such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge. In the
ordinary course of business, the Company and its Subsidiaries conduct periodic reviews of the effect of Environmental Laws on
their business and assets, in the course of which they identify and evaluate associated costs and liabilities (including, without
limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental
Laws or governmental permits issued thereunder, any related constraints on operating activities and any potential liabilities
to third parties). On the basis of such reviews, the Company and its Subsidiaries have reasonably concluded that such associated
costs and liabilities would not have, singularly or in the aggregate, a Material Adverse Change.

 

2.41
Real Property. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus, the Company
and each of its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use,
all items of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole,
in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate,
materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by
the Company or any of its Subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries,
considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration
Statement, the Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary
has received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company
or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company
or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.

 

2.42
Contracts Affecting Capital. There are no transactions, arrangements or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company’s or any of its Subsidiaries’ liquidity or the availability of or requirements for their capital
resources required to be described or incorporated by reference in the Registration Statement, the Disclosure Package and the
Prospectus which have not been described or incorporated by reference as required.

 

2.43
Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the time
of effectiveness of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or
another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of
the Shares and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405,
without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be
considered an ineligible issuer.

 

    	- 19 -

    	 

    

 

2.44
Industry Data. The statistical and market-related data included in each of the Registration Statement, the Disclosure Package
and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and
accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources.

 

2.45
Margin Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board
of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering
will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing
or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which
might cause any of the shares of Common Stock to be considered a “purpose credit” within the meanings of Regulation
T, U or X of the Federal Reserve Board.

 

2.46
Exchange Act Reports. The Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(a),
13(e), 14 and 15(d) of the Exchange Act during the preceding 12 months (except to the extent that Section 15(d) requires reports
to be filed pursuant to Sections 13(d) and 13(g) of the Exchange Act, which shall be governed by the next clause of this sentence);
and the Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(d) and 13(g) of the Exchange
Act since January 1, 2016, except where the failure to timely file could not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Change.

 

2.47
Minute Books. The minute books of the Company have been made available to the Placement Agents and counsel for the Placement
Agents, and such books (i) contain a complete summary of all meetings and actions of the Board (including each Board committee)
and stockholders of the Company (or analogous governing bodies and interest holders, as applicable), and each of its Subsidiaries
since the time of its respective incorporation or organization through the date of the latest meeting and action, except those
meetings protected by attorney client privilege, and (ii) accurately in all material respects reflect all transactions referred
to in such minutes. There are no material transactions, agreements, dispositions or other actions of the Company that are not
properly approved and/or accurately and fairly recorded in the minute books of the Company, as applicable, except as would not
be expected to have a Material Adverse Change.

 

2.48
Integration. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that
would cause the Offering to be integrated with prior offerings by the Company for purposes of the Securities Act that would require
the registration of any such securities under the Securities Act.

 

2.49
No Stabilization. Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the
consent of the Placement Agents) has taken or shall take, directly or indirectly, any action designed to or that has constituted
or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares.

 

2.50
Confidentiality and Non-Competition. To the Company’s knowledge, no director, officer, key employee or consultant
of the Company is subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with
any employer or prior employer that could reasonably be expected to materially affect his ability to be and act in his respective
capacity of the Company or be expected to result in a Material Adverse Change.

 

    	- 20 -

    	 

    

 

3.
Covenants of the Company. The Company
covenants and agrees as follows:

 

3.1
Amendments to Registration Statement. The Company shall deliver to the Placement Agents, prior to filing, any amendment
or supplement to the Registration Statement, Preliminary Prospectus, Disclosure Package or Prospectus proposed to be filed after
the Effective Date and not file any such amendment or supplement to which the Placement Agents shall reasonably object in writing.

 

3.2
Federal Securities Laws.

 

3.2.1
Compliance. The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 424(b) and Rule 430B of the
Securities Act Regulations, and will notify the Placement Agents promptly, and confirm the notice in writing, (i) when any post-effective
amendment to the Registration Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or
the Prospectus shall have been filed and when any post-effective amendment to the Registration Statement shall become effective;
(ii) of the receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration
Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus or for additional
information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus, the Disclosure
Package or the Prospectus, or of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, or
of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or
8(e) of the Securities Act concerning the Registration Statement; and (v) if the Company becomes the subject of a proceeding under
Section 8A of the Securities Act in connection with the Offering of the Shares. The Company shall effect all filings required
under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without
reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus
transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will
promptly file such prospectus. The Company shall use its best efforts to prevent the issuance of any stop order, prevention or
suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.

 

3.2.2
Continued Compliance. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act
and the Exchange Act Regulations so as to permit the completion of the distribution of the Shares as contemplated in this Agreement
and in the Registration Statement, the Disclosure Package and the Prospectus. If at any time when a prospectus relating to the
Shares is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (“Rule 172”), would
be) required by the Securities Act to be delivered in connection with sales of the Shares, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel for the Placement Agents or for the Company, to (i)
amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)
amend or supplement the Disclosure Package or the Prospectus in order that the Disclosure Package or the Prospectus, as the case
may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii)
amend the Registration Statement or amend or supplement the Disclosure Package or the Prospectus, as the case may be, in order
to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly (A) give the
Placement Agents notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement or
omission or to make the Registration Statement, the Disclosure Package or the Prospectus comply with such requirements and, a
reasonable amount of time prior to any proposed filing or use, furnish the Placement Agents with copies of any such amendment
or supplement and (C) file with the Commission any such amendment or supplement; provided, however, that the Company
shall not file or use any such amendment or supplement to which the Placement Agents or counsel for the Placement Agents shall
reasonably object. The Company will furnish to the Placement Agents such number of copies of such amendment or supplement as the
Placement Agents may reasonably request. The Company has given the Placement Agents notice of any filings made pursuant to the
Exchange Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Placement
Agents notice of its intention to make any such filing from the Applicable Time until the Closing Date and will furnish the Placement
Agents with copies of the related document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and
will not file or use any such document to which the Placement Agents or counsel for the Placement Agents shall reasonably object.

 

    	- 21 -

    	 

    

 

3.2.3
Exchange Act Registration. For a period of three (3) years after the date of this Agreement, the Company shall use its
best efforts to maintain the registration of the shares of Common Stock under the Exchange Act. The Company shall not deregister
the shares of Common Stock under the Exchange Act without the prior written consent of the Placement Agents.

 

3.2.4
Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Placement Agents,
it shall not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission
or retained by the Company under Rule 433; provided, however, that the Placement Agents shall be deemed to have
consented to each Issuer General Use Free Writing Prospectus hereto and any “road show that is a written communication”
within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Placement Agents. The Company represents that it has treated
or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Placement Agents as
an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable
requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record
keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development
as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading,
the Company will promptly notify the Placement Agents and will promptly amend or supplement, at its own expense, such Issuer Free
Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

 

3.3
Delivery to the Placement Agents of Registration Statements. The Company has delivered or made available or shall deliver
or make available to the Placement Agents and counsel for the Placement Agents, without charge, signed copies of the Registration
Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein
and documents incorporated or deemed to be incorporated by reference therein) and signed copies of all consents and certificates
of experts, and will also deliver to the Placement Agents, without charge, a conformed copy of the Registration Statement as originally
filed and each amendment thereto (without exhibits) for each of the Placement Agents. The copies of the Registration Statement
and each amendment thereto furnished to the Placement Agents will be identical to the electronically transmitted copies thereof
filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

 

    	- 22 -

    	 

    

 

3.4
Delivery to the Placement Agents of Prospectuses. The Company has delivered or made available or will deliver or make available
to the Placement Agents, without charge, as many copies of each Preliminary Prospectus as Placement Agent reasonably requested,
and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish
to the Placement Agents, without charge, during the period when a prospectus relating to the Shares is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as
amended or supplemented) as Placement Agent may reasonably request. The Prospectus and any amendments or supplements thereto furnished
to Placement Agent will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T.

 

3.5
Events Requiring Notice to the Placement Agents. The Company shall use its best efforts to cause the Registration Statement
to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Placement
Agents immediately and confirm the notice in writing: (i) of the issuance by the Commission of any stop order or of the initiation,
or the threatening, of any proceeding for that purpose; (ii) of the issuance by any state securities commission of any proceedings
for the suspension of the qualification of the Shares for offering or sale in any jurisdiction or of the initiation, or the threatening,
of any proceeding for that purpose; (iii) of the mailing and delivery to the Commission for filing of any amendment or supplement
to the Registration Statement or Prospectus; (iv) of the receipt of any comments or request for any additional information from
the Commission; and (v) of the happening of any event during the period described in this Section 3.5 that, in the judgment of
the Company, makes any statement of a material fact made in the Registration Statement, the Disclosure Package or the Prospectus
untrue or that requires the making of any changes in (a) the Registration Statement in order to make the statements therein not
misleading, or (b) in the Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend
such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.

 

3.6
Review of Financial Statements. For a period of five (5) years after the date of this Agreement, the Company, at its expense,
shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s
financial statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.

 

3.7
Listing. The Company shall use its best efforts to maintain the listing of the shares of Common Stock (including the Shares)
on the Exchange for at least three years from the date of this Agreement.

 

3.8
Financial Public Relations Firm. The Company has retained a financial public relations firm reasonably acceptable to the
Placement Agents and the Company and shall retain such firm or another firm reasonably acceptable to the Placement Agents for
a period of not less than two (2) years after the Effective Date.

 

3.9
Reports to the Placement Agents.

 

3.9.1
Periodic Reports, etc. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make
available to the Placement Agents copies of such financial statements and other periodic and special reports as the Company from
time to time furnishes generally to holders of any class of its securities and also promptly furnish to the Placement Agents:
(i) a copy of each periodic report the Company shall be required to file with the Commission under the Exchange Act and the Exchange
Act Regulations; (ii) a copy of every material press release and every material news item and article with respect to the Company
or its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared and filed by the Company; (iv) five copies
of each registration statement filed by the Company under the Securities Act; (v) a copy of each report or other communication
furnished to stockholders and (vi) such additional documents and information with respect to the Company and the affairs of any
future subsidiaries of the Company as the Placement Agents may from time to time reasonably request; provided, however,
the Placement Agents shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably
acceptable to the Placement Agents and Placement Agent Counsel in connection with the Placement Agents’ receipt of such
information. Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Placement
Agents pursuant to this Section 3.9.1.

 

    	- 23 -

    	 

    

 

3.9.2
Transfer Agent; Transfer Sheets. For a period of three (3) years after the date of this Agreement, the Company shall retain
a transfer agent and registrar acceptable to the Placement Agents (the “Transfer Agent”) and shall furnish
to the Placement Agents at the Company’s sole cost and expense such transfer sheets of the Company’s securities as
the Placement Agents may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent.
Nevada Agency & Transfer Company is acceptable to the Placement Agents to act as Transfer Agent for the shares of Common Stock.

 

3.9.3
Trading Reports. During such time as the Shares are listed on the Exchange, the Company shall provide to the Placement
Agents, at the Company’s expense, such reports published by Exchange relating to price trading of the Shares, as the Placement
Agents shall reasonably request.

 

3.10
Payment of Expenses. The Company hereby agrees to pay on the Closing Date all expenses incident to the performance of the
obligations of the Company under this Agreement, including, but not limited to: (i) all filing fees and communication expenses
relating to the registration of the shares to be sold in the offering with the Commission; (ii) all filing fees and expenses associated
with the review of the offering by FINRA; (iii) all fees and expenses relating to the listing of such shares on the Nasdaq Capital
Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE or the NYSE American and on such other stock exchanges
as the Company and the Placement Agents together determine, including any fees charged by The Depository Trust Company (DTC) for
new securities; (iv) all fees, expenses and disbursements relating to the registration or qualification of such shares under the
“blue sky” securities laws of such states and other jurisdictions as the Placement Agents may reasonably designate;
(v) all fees, expenses and disbursements relating to the registration, qualification or exemption of such shares under the securities
laws of such foreign jurisdictions as the Placement Agents may reasonably designate; (vi) the costs of all mailing and printing
of the offering documents; (vii) the costs of preparing, printing and delivering certificates representing the shares; (viii)
fees and expenses of the transfer agent for the shares; (ix) stock transfer and/or stamp taxes, if any, payable upon the transfer
of securities from the Company to the Placement Agents for the account of the investors; (x) all fees, expenses and disbursements
relating to background checks of the Company’s officers, directors and entities (xi) the costs associated with bound volumes
of the public offering materials as well as commemorative mementos and lucite tombstones, each of which the Company or its designee
will provide within a reasonable time after the closing in such quantities as the Placement Agents may reasonably request (xii)
the fees and expenses of the Company’s accountants; (xiii) the fees and expenses of the Company’s legal counsel and
other agents and representatives; (xiv) the fees and expenses of the Placement Agents’ legal counsel; (xv) the cost associated
with the use of Ipreo’s book building, prospectus tracking and compliance software for the offering; (xvi) data services
and communications expenses; (xvii) clearing and delivery expenses; and (xviii) the Placement Agents’ actual accountable
“road show” expenses for the offering. The reimbursement amount payable by the Company to the Placement Agents shall
not be more than an aggregate of $75,000 and shall be payable from the proceeds of the offering.

 

3.11
Application of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent
with the application thereof described under the caption “Use of Proceeds” in the Registration Statement, the Disclosure
Package and the Prospectus.

 

    	- 24 -

    	 

    

 

3.12
Delivery of Earnings Statements to Security Holders. The Company shall make generally available to its security holders
as soon as practicable, but not later than the first day of the fifteenth (15th) full calendar month following the
date of this Agreement, an earnings statement (which need not be certified by independent registered public accounting firm unless
required by the Securities Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under
Section 11(a) of the Securities Act) covering a period of at least twelve (12) consecutive months beginning after the date of
this Agreement.

 

3.13
Stabilization. Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the
consent of the Placement Agents) has taken or shall take, directly or indirectly, any action designed to or that has constituted
or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares.

 

3.14
Internal Controls. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable
assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions
are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability
for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization;
and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.

 

3.15
Accountants. As of the date of this Agreement, the Company shall continue to retain a nationally recognized independent
registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Placement Agents
acknowledges that Mayer Hoffman McCann P.C. is acceptable to the Placement Agents.

 

3.16
FINRA. The Company shall advise the Placement Agents (who shall make an appropriate filing with FINRA) if it is or becomes
aware that (i) any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company’s
securities or (iii) any beneficial owner of the Company’s unregistered equity securities which were acquired during the
180 days immediately preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA
member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

 

3.17
No Fiduciary Duties. The Company acknowledges and agrees that the Placement Agents’ responsibility to the Company
is solely contractual in nature and that none of the Placement Agents or their affiliates or any selling agent shall be deemed
to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection
with the Offering and the other transactions contemplated by this Agreement.

 

3.18
Reserved.

 

3.19
Company Lock-Up Agreements. The Company, on behalf of itself and any successor entity, agrees that, without the prior written
consent of the Placement Agents, it will not for a period of thirty (30) days after the date of this Agreement (the “Lock-Up
Period”), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly,
any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company; (ii) file or cause to be filed any registration statement with the Commission relating to the offering of
any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company; or (iii) complete any offering of debt securities of the Company, other than entering into a line of credit
with a traditional bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i),
(ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in
cash or otherwise.

 

    	- 25 -

    	 

    

 

The
restrictions contained in this Section 3.19 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance
by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding
on the date hereof, which is disclosed in the Registration Statement, Disclosure Package and Prospectus, provided that such options,
warrants, and securities have not been amended since the date of this Agreement to increase the number of such securities or to
decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities, (iii)
the issuance by the Company of stock options, shares of capital stock of the Company or other awards under any equity compensation
plan of the Company and (iv) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the
disinterested directors of the Company, provided that any such issuance shall only be to a Person (or to the equityholders of
a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic
with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or
to an entity whose primary business is investing in securities, provided that in each of (ii), (iii) and (iv) above, the underlying
shares shall be restricted from sale during the entire Lock-Up Period.

 

3.20
Release of D&O Lock-up Period. If the Placement Agents, in their sole discretion, agree to release or waive the restrictions
set forth in the Lock-Up Agreements described in Section 2.27 hereof for an officer or director of the Company and provide the
Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release
or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit
B hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.

 

3.21
Blue Sky Qualifications. The Company shall use its best efforts, in cooperation with the Placement Agents, if necessary,
to qualify the Shares for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic
or foreign) as the Placement Agents may designate and to maintain such qualifications in effect so long as required to complete
the distribution of the Shares; provided, however, that the Company shall not be obligated to file any general consent
to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not
so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so
subject.

 

3.22
Reporting Requirements. The Company, during the period when a prospectus relating to the Shares is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Shares as may be required under Rule 463 under
the Securities Act Regulations.

 

3.23
Press Releases. Prior to the Closing Date, the Company shall not issue any press release or other communication directly
or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business
affairs or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent
with the past practices of the Company and of which the Placement Agents are notified), without the prior written consent of the
Placement Agents, which consent shall not be unreasonably withheld, unless in the judgment of the Company and its counsel, and
after notification to the Placement Agents, such press release or communication is required by law.

 

    	- 26 -

    	 

    

 

3.24
Sarbanes-Oxley. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company
shall at all times comply with all applicable provisions of the Sarbanes-Oxley Act in effect from time to time.

 

4.
Conditions of Placement Agents’ Obligations.
The obligations of the Buyers to purchase and pay for the Shares, as provided in the Securities Purchase Agreement, and the obligations
of the Placement Agents to arrange for the aggregate purchase amount to be paid to the Company, shall be subject to (i) the continuing
accuracy of the representations and warranties of the Company as of the date hereof and as of each of the Closing Date; (ii) the
accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company
of its obligations hereunder; and (iv) the following conditions:

 

4.1
Regulatory Matters.

 

4.1.1
Commission Actions; Required Filings. At the Closing Date, no stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto shall have been issued under the Securities Act, no order preventing or suspending
the use of any Preliminary Prospectus or the Prospectus shall have been issued and no proceedings for any of those purposes shall
have been instituted or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied
with each request (if any) from the Commission for additional information. A prospectus containing the Rule 430B Information shall
have been filed with the Commission in the manner and within the time frame required by Rule 424(b) under the Securities Act Regulations
(without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and
declared effective by, the Commission in accordance with the requirements of Rule 430B under the Securities Act Regulations.

 

4.1.2
FINRA Clearance. On or before the date of this Agreement, the Placement Agents shall have received clearance from FINRA
as to the amount of compensation allowable or payable to the Placement Agents as described in the Registration Statement.

 

4.1.3
Exchange Stock Market Clearance. On the Closing Date, the Company’s shares of Common Stock, including the Shares,
shall have been approved for listing on the Exchange, subject only to official notice of issuance.

 

4.2
Company Counsel Matters.

 

4.2.1
Closing Date Opinion of Counsel. On the Closing Date, the Placement Agents shall have received the opinion of Alston &
Bird LLP, counsel to the Company, and a written statement providing certain “10b-5” negative assurances, dated the
Closing Date and addressed to the Placement Agents and each Other Investor not party to the Securities Purchase Agreement, substantially
in the form of Exhibit C attached hereto.

 

4.2.2
Reliance. In rendering such opinion, such counsel may rely: (i) as to matters involving the application of laws other than
the laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the
extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the
Placement Agents) of other counsel reasonably acceptable to the Placement Agents, familiar with the applicable laws; and (ii)
as to matters of fact, to the extent they deem proper, on certificates or other written statements of officers of the Company
and officers of departments of various jurisdictions having custody of documents respecting the corporate existence or good standing
of the Company; provided that copies of any such statements or certificates shall be delivered to Placement Agents’
counsel if requested.

 

    	- 27 -

    	 

    

 

4.3
Comfort Letters.

 

4.3.1
Cold Comfort Letter. At the time this Agreement is executed you shall have received cold comfort letters from the Auditors
containing statements and information of the type customarily included in accountants’ comfort letters with respect to the
financial statements and certain financial information contained or incorporated or deemed incorporated by reference in the Registration
Statement, the Disclosure Package and the Prospectus, addressed to the Placement Agents and in form and substance satisfactory
in all respects to you and to the Auditors, dated as of the date of this Agreement.

 

4.3.2
Bring-down Comfort Letter. At the Closing Date the Placement Agents shall have received from the Auditors a letter, dated
as of the Closing Date to the effect that the Auditors reaffirm the statements made in their letters furnished pursuant to Section
4.3.1, except that the specified date referred to shall be a date not more than three (3) business days prior to the Closing Date,
as applicable.

 

4.4
Officers’ Certificates.

 

4.4.1
Officer’s Certificate. The Company shall have furnished to the Placement Agents and each Other Investor not party
to the Securities Purchase Agreement a certificate, dated the Closing Date, of its Chief Executive Officer stating that (i) such
officer has carefully examined the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the
Prospectus and, in his opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the
Closing Date did not include any untrue statement of a material fact and did not omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, and the Disclosure Package, as of the Applicable Time
and as of the Closing Date, any Issuer Free Writing Prospectus as of its date and as of the Closing Date, and the Prospectus and
each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue
statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances in which they were made, not misleading, (ii) since the effective date of the Registration Statement,
no event has occurred which should have been, and was not, set forth in a supplement or amendment to the Registration Statement,
the Disclosure Package or the Prospectus, (iii) to the best of his knowledge after reasonable investigation, as of the Closing
Date, the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with
all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date,
and (iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by
reference in the Disclosure Package, any material adverse change in the financial position or results of operations of the Company,
or any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective material
adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of
the Company, except as set forth in the Prospectus.

 

4.4.2
Secretary’s Certificate. At the Closing Date, the Placement Agents shall have received a certificate of the Company
signed by the Secretary of the Company, dated the Closing Date certifying: (i) that each of the Charter and Bylaws is true and
complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Board relating to the Offering
are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between
the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred
to in such certificate shall be attached to such certificate.

 

    	- 28 -

    	 

    

 

4.5
No Material Changes. Prior to and on the Closing Date: (i) there shall have been no material adverse change or development
involving a prospective material adverse change in the condition or prospects or the business activities, financial or otherwise,
of the Company from the latest dates as of which such condition is set forth in the Registration Statement and no change in the
capital stock or debt of the Company, the Disclosure Package and the Prospectus; (ii) no action, suit or proceeding, at law or
in equity, shall have been pending or threatened against the Company or any Insider before or by any court or federal or state
commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may materially adversely affect
the business, operations, prospects or financial condition or income of the Company, except as set forth in the Registration Statement,
the Disclosure Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings
therefor shall have been initiated or threatened by the Commission; (iv) no action shall have been taken and no law, statute,
rule, regulation or order shall have been enacted, adopted or issued by any Governmental Entity which would prevent the issuance
or sale of the Shares or materially and adversely affect or potentially materially and adversely affect the business or operations
of the Company; (v) no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction
shall have been issued which would prevent the issuance or sale of the Shares or materially and adversely affect or potentially
materially and adversely affect the business or operations of the Company and (vi) the Registration Statement, the Disclosure
Package and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required
to be stated therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material
respects to the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration Statement,
the Disclosure Package, the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading.

 

4.6
Corporate Proceedings. All corporate proceedings and other legal matters incident to the authorization, form and validity
of each of this Agreement, the Shares, the Registration Statement, the Disclosure Package and the Prospectus and all other legal
matters relating to this Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory in all
material respects to counsel for the Placement Agents, and the Company shall have furnished to such counsel all documents and
information that they may reasonably request to enable them to pass upon such matters.

 

4.7
Delivery of Agreements.

 

4.7.1
Lock-Up Agreements. On or before the date of this Agreement, the Company shall have delivered to the Placement Agents executed
copies of the Lock-Up Agreements from each of the persons listed in Schedule 3 hereto.

 

4.8
Additional Documents. At the Closing Date, Placement Agent Counsel shall have been furnished with such documents and opinions
as they may require for the purpose of enabling Placement Agent Counsel to deliver an opinion to the Placement Agents, or in order
to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained;
and all proceedings taken by the Company in connection with the issuance and sale of the Shares as herein contemplated shall be
satisfactory in form and substance to the Placement Agents and Placement Agent Counsel.

 

    	- 29 -

    	 

    

 

5.
Indemnification.

 

5.1
Indemnification of the Placement Agents. In consideration of the Placement Agents’ execution and delivery of, and
the performance of their respective obligations under, this Agreement, and in addition to all of the Company’s other obligations
under the Offering Documents, the Company shall defend, indemnify and hold harmless each Placement Agent, each of their respective
Affiliates, each Person, if any, who controls either Placement Agent or any of their respective Affiliates within the meaning
of Section 15 of the Act or Section 20 of the Exchange Act, and each of their directors, officers, partners, members, shareholders,
direct or indirect investors, employees, representatives and agents (including, without limitation, those attorneys, sub-placement
agents and other agents retained by the Placement Agents or any such other Person in connection with the transactions contemplated
by this Agreement and the other Offering Documents) (collectively, the “Placement Agent Indemnified Parties,”
and each a “Placement Agent Indemnified Party”), from and against any and all claims, actions, causes of action,
suits, proceedings (including, without limitation, as a party in interest or otherwise in any action or proceeding for injunctive
or other equitable relief), including, without limitation, any and all derivative actions brought on behalf of the Company or
any Subsidiary, and any and all civil, criminal or regulatory investigations, whether formal or informal, to which any Placement
Agent Indemnified Party may become subject (irrespective of whether any such Placement Agent Indemnified Party is a party, threatened
to be made a party, or a witness to the claim, action, cause of action, suit, proceeding or investigation for which indemnification
hereunder is sought), and all damages, losses, liabilities and expenses (including the reasonable fees and expenses of counsel)
incurred by any Placement Agent Indemnified Party (including, without limitation, in settlement of any claim, action, cause of
action, suit, proceeding or investigation), in each case as incurred (collectively, a “Claim”), as a result
of, or arising out of, or relating to (i) any misrepresentation, inaccuracy or breach of any representation or warranty made by
the Company or any Subsidiary in this Agreement or in the Registration Statement, the Disclosure Package, any Issuer Free Writing
Prospectus and the Prospectus, (ii) any breach of any covenant, agreement or obligation of the Company or any Subsidiary contained
in this Agreement or in the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus,
(iii) the execution, delivery, performance or enforcement of this Agreement or the Registration Statement, the Disclosure Package,
any Issuer Free Writing Prospectus and the Prospectus, (iv) any transaction financed or to be financed in whole or in part, directly
or indirectly, with the proceeds of the issuance of the Securities, (v) any untrue statement or alleged untrue statement of a
material fact contained in any the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the
Prospectus, or any amendment thereto, or the omission or alleged omission therefrom of a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (vi)
the status of such Placement Agent Indemnified Party as a holder of any equity or debt securities of the Company or any of its
subsidiaries, including, without limitation, any of the Securities or the Placement Agents Securities, or as a party (or agent
or attorney of such party) to this Agreement, (vii) any act or failure to act or any alleged act or failure to act by any Placement
Agent Indemnified Party in connection with, or relating in any manner to, the Securities, the Offering or any of the transactions
contemplated by this Agreement, provided that the Company shall not be liable under this clause (vii) to the extent that a court
of competent jurisdiction shall have determined by a final, non-appealable judgment that such claim, action, cause of action,
suit, proceeding, investigation, damage, loss, liability or expense resulted exclusively from the bad faith or willful misconduct
of such Placement Agent Indemnified Party; and to reimburse such Placement Agent Indemnified Party for any and all expenses (including
the reasonable fees and disbursements of counsel chosen by such Placement Agent Indemnified Party) as such expenses are incurred
by such Placement Agent Indemnified Party in connection with investigating, defending, settling, compromising or paying any such
claim, action, cause of action, suit, proceeding, investigation, damage, loss, liability or expense. To the extent that the foregoing
undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment
and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law.

 

    	- 30 -

    	 

    

 

5.2
Notifications and Other Indemnification Procedures. Promptly after receipt by a Placement Agent Indemnified Party under
this Section 5 of notice of the commencement of any action, such Placement Agent Indemnified Party will, if a claim in respect
thereof is to be made against the Company under this Section 5, notify the Company in writing of the commencement thereof, but
the omission so to notify the Company will not relieve it from any liability, which it may have to any Placement Agent Indemnified
Party for contribution to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought
against any Placement Agent Indemnified Party and the such Placement Agent Indemnified Party seeks or intends to seek indemnity
from the Company, the Company will be entitled to participate in, and, by written notice delivered to such Placement Agent Indemnified
Party promptly after receiving the aforesaid notice from such Placement Agent Indemnified Party, to assume the defense thereof
with counsel reasonably satisfactory to such Placement Agent Indemnified Party; provided, however, if the defendants
in any such action include both the Placement Agents Indemnified Party and the Company, and the Placement Agents Indemnified Party
shall have reasonably concluded that a conflict may arise between the positions of the Company and the Placement Agents Indemnified
Party in conducting the defense of any such action or that there may be legal defenses available to it and/or other Placement
Agent Indemnified Parties which are different from or additional to those available to the Company, such Placement Agent Indemnified
Party or Placement Agent Indemnified Parties shall have the right to select separate counsel to assume such legal defenses and
to otherwise participate in the defense of such action on behalf of such Placement Agent Indemnified Party or Placement Agent
Indemnified Parties. Upon receipt of notice from the Company to the Placement Agents Indemnified Party of the Company’s
election so to assume the defense of such action and approval by such Placement Agent Indemnified Party of counsel, the Company
will not be liable to such Placement Agent Indemnified Party under this Section 8 for any legal or other expenses subsequently
incurred by such Placement Agent Indemnified Party in connection with the defense thereof unless: (i) the Placement Agents Indemnified
Party shall have employed separate counsel in accordance with the proviso to the next preceding sentence (it being understood,
however, that the Company shall not be liable for the expenses of more than one separate counsel (together with local counsel),
approved by the Company), representing the Placement Agents Indemnified Parties who are parties to such action); (ii) the Company
shall not have employed counsel satisfactory to the Placement Agents Indemnified Party to represent the Placement Agents Indemnified
Party within a reasonable time after notice of commencement of the action; or (iii) the Company has authorized the employment
of counsel for the Placement Agents Indemnified Party at the expense of the Company, in each of which cases the fees and expenses
of counsel shall be at the expense of the Company.

 

5.3
Settlements. The Company shall not be liable under this Section 5 for any settlement of any proceeding effected without
its written consent, which consent shall not be unreasonably conditioned, withheld or delayed, but if settled with such consent
or if there be a final judgment for the plaintiff, the Company agrees to indemnify the applicable Placement Agent Indemnified
Party or Placement Agent Indemnified Parties against any claim, action, cause of action, suit, proceeding, investigation, damage,
loss, liability or expense by reason of such settlement or judgment. The Company shall not, without the prior written consent
of the Placement Agents Indemnified Party, effect any settlement, compromise or consent to the entry of judgment in any pending
or threatened action, suit or proceeding in respect of which any Placement Agent Indemnified Party is or could have been a party
and indemnity was or could have been sought hereunder by such Placement Agent Indemnified Party, unless such settlement, compromise
or consent includes: (i) an unconditional release of such Placement Agent Indemnified Party from all liability on claims that
are the subject matter of such action, suit or proceeding; and (ii) does not include a statement as to or an admission of fault,
culpability or a failure to act by or on behalf of any Placement Agent Indemnified Party.

 

    	- 31 -

    	 

    

 

5.4
Contribution. If the indemnification provided for in this Section 5 is unavailable to or insufficient to hold harmless
a Placement Agent Indemnified Party under Section 5(a) above in respect of any claim, action, cause of action, suit, proceeding,
investigation, damage, loss, liability or expense, then the Company shall contribute to the aggregate amount paid or payable by
such Placement Agent Indemnified Party in such proportion as is appropriate to reflect the relative benefits received by the Company,
on the one hand, and such Placement Agent Indemnified Party, on the other, from the Offering. If, however, the allocation provided
by the immediately preceding sentence is not permitted by applicable law then the Company shall contribute to such amount paid
or payable by such Placement Agent Indemnified Party in such proportion as is appropriate to reflect not only such relative benefits
but also the relative fault of the Company, on the one hand, and such Placement Agent Indemnified Party, on the other, in connection
with the actions or omissions which resulted in such losses, claims, damages or liabilities (or actions or proceedings in respect
thereof), as well as any other relevant equitable considerations. The relative fault shall be determined by reference to, among
other things, the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such
action or omission.

 

The
Company and Placement Agents agree that it would not be just and equitable if contributions pursuant to this Section 5(d) were
determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations
referred to above in this Section 5(d). The amount paid or payable by a Placement Agent Indemnified Party as a result of the losses,
claims, damages or liabilities (or actions or proceedings in respect thereof) referred to above in this Section 5(d) shall be
deemed to include any legal or other expenses reasonably incurred by such Placement Agent Indemnified Party in connection with
investigating or defending any such claim, action, cause of action, suit, proceeding or investigation. Notwithstanding the provisions
of this subsection (d): (i) the Placement Agents shall not be required to contribute any amount in excess of the amount of the
Cash Fee actually received by Placement Agent pursuant to this Agreement; and (ii) no person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation.

 

5.5
Timing of Any Payments of Indemnification. Any losses, claims, damages, liabilities or expenses for which a Placement Agent
Indemnified Party is entitled to indemnification or contribution under this Section 5 shall be paid by the Company to the Placement
Agents Indemnified Party as such losses, claims, damages, liabilities or expenses are incurred, but in all cases, no later than
fifteen (15) days of invoice to the Company.

 

5.6
Acknowledgements of Parties. The parties to this Agreement hereby acknowledge that they are sophisticated business persons
who were represented by counsel during the negotiations regarding the provisions hereof including, without limitation, the provisions
of this Section 5, and are fully informed regarding said provisions. They further acknowledge that the provisions of this Section
5 fairly allocate the risks in light of the ability of the parties to investigate the Company and its business in order to assure
that adequate disclosure is made in the Disclosure Package.

 

6.
Miscellaneous.

 

6.1
Notices. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall
be mailed (registered or certified mail, return receipt requested), personally delivered or sent by e-mail or facsimile transmission
and confirmed and shall be deemed given when so delivered, e-mailed or faxed and confirmed or if mailed, two (2) days after such
mailing.

 

If
to the Placement Agents:

 

ThinkEquity,
a division of Fordham Financial Management, Inc.

17 State Street, 22nd Floor

New York, New York 10004

Attention: Mr. Eric Lord, Head of Investment Banking

Fax No.: (212) 349-2550

E-mail:
el@think-equity.com

 

    	- 32 -

    	 

    

 

Torreya
Capital, LLC

555
Madison Avenue, Suite 1201

New
York • NY 10022

Attention:
Mr. Tim Opler, Ph.D.

E-mail:
tim.opler@torreya.com

 

with
a copy (which shall not constitute notice) to:

 

Loeb
& Loeb LLP

345 Park Avenue

New York, NY 10154

Attn:
Mitchell S. Nussbaum, Esq.

Fax
No.: (212) 504-3013

 

If
to the Company:

 

OncoSec
Medical Incorporated

24
North Main Street

Pennington,
NJ 08534

Telephone:
(855) 662-6732

Facsimile:

Attention:
Chief Executive Officer

E-Mail:
doconnor@oncosec.com

 

With
a copy (which shall not constitute notice) to:

 

Alston
& Bird LLP

90
Park Avenue

New
York, NY 10016

Attention: Matthew Mamak, Esq.

Fax
No: (212) 922-3952

 

6.2
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way
limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

 

6.3
Amendment. This Agreement may only be amended by a written instrument executed by each of the parties hereto.

 

6.4
Entire Agreement. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof,
and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.
Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms
and conditions of that certain engagement letter between the Company and ThinkEquity, a division of Fordham Financial Management,
Inc. and Torreya Partners, LLC, dated August 15, 2020, shall remain in full force and effect.

 

    	- 33 -

    	 

    

 

6.5
Binding Effect. This Agreement shall inure solely to the benefit of and shall be binding upon the Placement Agents, the
Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors,
legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right,
remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained.

 

6.6
Governing Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in
accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby
agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought
and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any
objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to
be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested,
postage prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal service
and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies)
in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses
relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf
and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Placement Agents
hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

 

6.7
Execution in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one
and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto
and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf
transmission shall constitute valid and sufficient delivery thereof.

 

6.8
Waiver, etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall
not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any
provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and
no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent
breach, non-compliance or non-fulfillment.

 

[Signature
Page Follows]

 

    	- 34 -

    	 

    

 

If
the foregoing correctly sets forth the understanding between the Placement Agents and the Company, please so indicate in the space
provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.

 

	 	Very truly yours,
	 	 
	 	ONCOSEC
    MEDICAL INCORPORATED
	 	 	 
	 	By:	/s/
    Dan O’Connor
	 	Name:	Dan O’Connor
	 	Title:	Chief Executive
    Officer

 

Confirmed
as of the date first written above mentioned

 

THINKEQUITY

 

A
Division of Fordham Financial Management, Inc.

 

	By:	/s/
    Eric Lord	 
	Name:	Eric Lord	 
	Title:	Head of Investment Banking	 
	 	 	 
	TORREYA CAPITAL, LLC	 
	 	 	 
	By:	/s/
    Tim Opler	 
	Name:	Tim Opler	 
	Title:	Principal	 

 

[Signature
Page to Placement Agency Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]